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PREFACE
The Occupational Safety and Health Act of 1970 emphasizes the need 
for standards to protect the health and safety of workers exposed to an 
ever-increasing number of potential hazards at their workplace. The 
National Institute for Occupational Safety and Health has projected a 
formal system of research, with priorities determined on the basis of 
specified indices, to provide relevant data from which valid criteria for 
effective standards can be derived. Recommended standards for occupational 
exposure, which are the result of this work, are based on the health 
effects of exposure. The Secretary of Labor will weigh these 
recommendations along with other considerations such as feasibility and 
means of implementation in developing regulatory standards.
It is intended to present successive reports as research and 
epidemiologic studies are completed and sampling and analytical methods are 
developed. Criteria and standards will be reviewed periodically to ensure 
continuing protection of the worker.
I am pleased to acknowledge the contributions to this report on 
chloroform by members of my staff and the valuable constructive comments by 
the Review Consultants on Chloroform, by the ad hoc committee of the 
American Conference of Governmental Industrial Hygienists, by Robert B. 
O'Connor, M.D., NIOSH consultant in occupational medicine, and by Edwin C. 
Hyatt, NIOSH consultant on respiratory protection. The NIOSH 
recommendations for standards are not necessarily a consensus of all the
consultants and the professional society that reviewed this criteria 
document on chloroform. Lists of the NIOSH Review Committee members and of 
the Review Consultants appear on the following pages.
Marcus M. Key, M.D.
Director, National Institute for 
Occupational Safety and Health
The Office of Research and Standards Development, 
National Institute for Occupational Safety and 
Health, had primary responsibility for development 
of the criteria and recommended standard for chloroform. 
Agatha Corporation developed the basic information 
for consideration by NIOSH staff and consultants under 
contract No HSM-99-73-20. Keith H. Jacobson, Ph.D., had 
program responsibility and Stanley C. Mazaleski, Ph.D., 
served as criteria manager.
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I. RECOMMENDATIONS FOR A CHLOROFORM STANDARD
The National Institute for Occupational Safety and Health (NIOSH) 
recommends that worker exposure to chloroform (CHC13) in the workplace be 
controlled by adherence to the following sections. The standard is
designed to protect the health and safety of workers for up to a 10-hour 
day, 40-hour week over a working lifetime; compliance with the standard 
should therefore prevent adverse effects of chloroform on the health and 
safety of workers. The standard is measurable by techniques that are 
valid, reproducible, and available to industry and governmental agencies. 
Sufficient technology exists to permit compliance with the recommended 
standard. The standard will be subject to review and revision as
necessary.
"Exposure to chloroform" is defined as exposure above half the time- 
weighted average (TWA) environmental limit. Exposures at lower 
environmental concentrations will not require adherence to the following 
sections, except for Sections 4 (b) and (c) and Section 6 (d).
Section 1 - Environmental (Workplace Air)
(a) Concentration
Occupational exposure shall be controlled so that no worker will be 
exposed to chloroform in excess of 10 ppm (48.9 mg/cu m) determined as a
time-weighted average exposure for up to a 10-hour workday, 40-hour
workweek, or for any 10-minute period to more than 50 ppm (244 mg/cu m).
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(b) Sampling and Analysis
The procedure for sampling and analysis of workroom air for compli­
ance with the standard shall be as provided in Appendix I, or by any method 
shown to be equivalent or better in precision, sensitivity, accuracy, and 
specificity.
Section 2 - Medical
(a) Comprehensive preplacement medical examinations shall be 
made available to all workers subject to "exposure to chloroform" and 
yearly thereafter, unless a different frequency is indicated by 
professional medical judgment.
(b) These examinations shall include, but shall not be limited
to:
(1) A comprehensive or interim medical and work history 
giving special attention to gastrointestinal symptoms and mental status. 
The worker's alcohol consumption should be reviewed.
(2) A comprehensive medical examination, giving 
particular attention to cardiac rhythm, liver and kidney function. Liver 
function tests and urinalysis shall be performed.
(3) An evaluation of the advisability of the worker's 
using negative- or positive-pressure respirators.
(4) Proper medical management shall be provided for 
workers adversely affected by chloroform.
(c) The medical representatives of the Secretary of Health, 
Education, and Welfare, of the Secretary of Labor, of the employee or
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former employee, and of the employer shall have access to all medical 
records.
(d) Medical records shall be maintained for persons employed one 
or more years in work involving exposure to chloroform. All medical 
records with pertinent supporting documents shall be maintained at least 5 
years after the individual's employment is terminated.
Section 3 - Labeling (Posting)
The following warning sign shall be affixed in a readily visible 
location on processing and other equipment, on chloroform storage tanks, or 
containers, at or near entrances to areas in which there is occupational 
exposure to chloroform:
CHLOROFORM 
DANGER: INHALATION MAY BE
HAZARDOUS TO HEALTH.
Keep containers closed when not in use.
Use only with adequate ventilation.
Avoid breathing vapor.
Avoid contact with skin.
May generate toxic phosgene gas on contact 
with flame or very hot metal surface.
This warning sign shall be printed both in English and in the pre­
dominant language of non-English-speaking workers, if any, unless they are
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otherwise trained and informed of the hazardous conditions. All illiterate 
workers shall receive such training.
If exposures to chloroform in the workroom exceed the recommended 
standard, and a variance permitting the use of respiratory controls has 
been granted, the following shall be added to the sign: No worker allowed
to enter area without proper respiratory protection.
Section 4 - Personal Protective Equipment and Clothing
When the limit of exposure to chloroform prescribed in subsection
(a) of Section 1 cannot be met through application of available engineering 
controls in the design of equipment, systems, or operating procedures, an 
employer must utilize, as provided in subsection (a) of this Section, a
program of respiratory protection to effect the required protection of
every worker exposed.
(a) Respiratory Protection
Appropriate respirators shall be provided and used when a variance 
has been granted to allow respirators as a means of control of exposure to
routine operations and while the application is pending. Administrative
controls can be used to reduce exposure. Respirators shall also be
provided and used for nonroutine operations (occasional brief exposures 
above the standard and for emergencies); however, for these instances a 
variance is not required but the requirements set forth below continue to 
apply. Appropriate respirators as described in Table 1-1 shall only be
used pursuant to the following requirements:
(1) For the purpose of determining the type of respira­
tor to be used, the employer shall measure the atmospheric concentration of
chloroform in the workplace when the initial application for variance is 
made and thereafter whenever process, worksite, climate, or control changes 
occur which are likely to increase the chloroform concentration. This 
requirement shall not apply when only atmosphere-supplying positive 
pressure respirators are used.
(2) The respirator and cartridge or canister used shall 
be of the appropriate class, as determined on the basis of exposure to 
chloroform. The employer shall ensure that no worker is being exposed to 
chloroform in excess of the standard because of improper respirator 
selection, fit, use, or maintenance.
(3) A respiratory protective program meeting the general 
requirements outlined in Section 3.5 of American National Standard Prac­
tices for Respiratory Protection Z88.2-1969 shall be established and en­
forced by the employer. In addition, Sections 3.6 (Program Administra­
tion), 3.7 (Medical Limitations), and 3.8 (Approval) shall be adopted and 
enforced.
(4) The employer shall provide respirators in accordance 
with Table 1-1 and shall ensure that the employee uses the respirator 
provided.
(5) Respiratory protective devices described in Table I- 
1 shall be those approved under provisions of 30 CFR 11.
(6) Respirators specified for use in higher concentra­
tions of chloroform are permitted in atmospheres of lower concentrations.
(7) Chemical cartridges and canisters shall not be used 
for periods of time in excess of those indicated in Table 1-1.
5
(8) Employees shall be given instruction on the use of 
respirators assigned to them, cleaning of the respirators, and how to test 
for leakage.
(9) Wherever bulk chloroform is handled, emergency and
escape-type respirators shall be made readily available for each worker.
Continuous contact must be maintained with employees working in enclosed
spaces where chloroform concentration may become excessive.
(b) Protective Clothing
In any operation where the worker may come into direct contact with
liquid chloroform, protective clothing shall be worn. The clothing must be 
both impervious and resistant (such as neoprene or polyvinyl chloride) to 
chloroform. Bib-type aprons should be at least knee length, gloves should 
be lined to absorb perspiration, and boots or overshoes shall be provided 
when necessary. Impervious supplied air hoods or suits should be worn when 
entering areas with limited egress such as pits or tanks. All protective 
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Evacuation or Escape 
(no concentration 
limit)
REQUIREMENTS FOR RESPIRATOR USAGE
Respirator Type
1) Chemical cartridge respirator vith 
replaceable organic vapor cartridge 
with half or full facepiece. Maxi­
mum service life of 3 hours.
2) Full face gas mask, chin type, with 
organic vapor canister. Maximum 
life of 4 hours.
3) Type C supplied air respirator, demand 
type (negative pressure), with half 
mask facepiece.
1) Full face gas mask, chest or back 
mounted type, with industrial size 
organic vapor canister. Maximum 
service life of 2 hours.
2) Type C supplied air respirator, demand 
type (negative pressure), with full 
facepiece.
1) Type C supplied air respirator, con­
tinuous flow or pressure-demand type 
(positive pressure) with full face­
piece, hood or helmet.
1) Self-contained breathing apparatus with 
positive pressure in full facepiece.
2) Combination supplied air respirator 
pressure-demand type, with auxiliary 
self-contained air supply.
1) Self-contained breathing apparatus 
with positive pressure in facepiece.
2) Combination supplied air respirator, 
pressure-demand type, with auxiliary 
self-contained air supply.
1) Self-contained breathing apparatus in 
demand or pressure-demand mode (negative 
or positive pressure).
2) Full-face gas mask, front or back mount 
type with industrial size organic vapor 
canister.
3) Mouthpiece respirator with escape type 




Eye protection shall be provided for any employee engaged in an 
operation where chloroform liquid or mist may enter the eye. Chemical-type 
goggles, safety glasses with splash shields, or plastic face shields made 
completely of chloroform resistant materials shall be used.
Suitable eye protection shall be provided in accordance with 29 CFR 
1910.133.
Section 5 - Informing Employees of Hazards from Chloroform
At the beginning of employment in a chloroform area, each employee 
shall be informed of the hazards, relevant symptoms, effects of 
overexposure to and the proper conditions and precautions concerning safe 
use and handling of chloroform.
The information explaining the hazards of working with chloroform 
shall be kept on file and readily accessible to the worker at all places of 
employment where chloroform is manufactured, used, stored, or transported.
A continuing educational program shall be instituted to ensure that 
all workers have current knowledge of job hazards, proper maintenance 
procedures, and cleanup methods, and that they know how to correctly use 
respiratory protective equipment and protective clothing.
Information on file and readily accessible to workers shall include 
that specified in Appendix II, on US Department of Labor Form 0SHA-2Q 
"Material Safety Data Sheet", or a similar form approved by the Occupa­
tional Safety and Health Administration, US Department of Labor.
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Section 6 - Work Practices
(a) Handling and Storage
(1) Where employees are required to enter confined areas
where containers of chloroform are stored, such as a delivery van, entry
shall not be made until the space has been ventilated or checked for
concentrations of chloroform.
(2) Storage containers, piping, and valves shall be 
periodically checked for leakage.
(3) Storage facilities shall be designed to contain 
spills and prevent contamination of workroom air.
(b) Contaminant Controls
Suitable engineering controls designed to limit exposure to 
chloroform to that prescribed in subsection (a) of Section 1 shall be 
utilized where appropriate and feasible. Where ventilation systems are 
used to achieve such control, they shall be designed to prevent the 
accumulation or recirculation of chloroform in the workroom and to 
effectively remove chloroform from the breathing zones of workers. 
Ventilation systems shall be subjected to regular preventive maintenance
and cleaning to ensure maximum effectiveness, which shall be verified by 
periodic airflow measurements. In addition, necessary measures shall be 
taken to ensure that discharge outdoors will be in conformance with all 
appropriate environmental regulations.
(c) Equipment Maintenance and Emergency Procedures
Air saturated with chloroform is immediately dangerous to life and 
if a limited egress situation exists, emergency procedures must be 
established and followed.
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(1) Chloroform hazard areas
Exits shall be plainly marked. Emergency exit doors shall 
be conveniently located and shall open to areas which will remain free of 
contamination in an emergency.
(2) Confined spaces
(A) Entry into confined spaces or in other
situations of limited egress shall be controlled by a permit system. 
Permits shall be signed by an authorized representative of the employer
certifying that preparation of the confined space, precautionary measures,
personal protective equipment, and procedures to be used are all adequate.
(B) Tanks, pits, tank cars, process vessels, 
tunnels, sewers, etc, which have contained chloroform, shall be thoroughly 
ventilated, tested for chloroform, and inspected prior to entry.
(C) Inadvertent entry of chloroform into the 
confined space while work is in process inside shall be prevented by 
disconnecting and blanking off chloroform supply lines.
(D) Confined spaces shall be ventilated or 
otherwise maintained to keep the chloroform concentration below the limit 
and to prevent oxygen deficiency.
(E) Personnel entering confined spaces shall be 
equipped with a lifeline tended by another worker outside the space who 
shall be equipped with approved respiratory, eye, and skin protection.
(F) Written operating instructions and emergency 
medical procedures shall be formulated and posted in conspicuous locations 
where accidental exposure to anesthetic concentrations of chloroform may 
occur. These instructions and procedures shall be printed both in English
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and in the predominant language of non-English-speaking workers, if any, 
unless they are otherwise trained and informed of the hazardous areas. All 
illiterate workers shall receive such training.
(d) Showers and Eye Wash Fountains
Showers and eye wash fountains shall be provided and so located as 
to be readily accessible in all areas where skin or eye splash with 
chloroform is likely. If chloroform is splashed on the skin, contaminated 
clothing shall be promptly removed and the skin washed with soap and water. 
If liquid chloroform contacts the eyes, they shall be thoroughly irrigated 
with clean water. Medical assistance shall be promptly provided in cases 
of eye splash. Such incidents shall be reported to the immediate 
supervisor by the affected employee or by a fellow worker.
Section 7 - Monitoring and Recordkeeping
Workroom areas where it has been determined, on the basis of a 
professional industrial hygiene survey or the judgment of a compliance 
officer, that the environmental concentrations do not result in TWA workday 
exposures above half the TWA environmental limit shall not be considered to 
have chloroform exposure. Records of these surveys, including the basis 
for concluding that the exposures are at or below half the limit, shall be 
maintained until a new survey is conducted. Surveys shall be repeated when 
any process change indicates a need for réévaluation or at the discretion 
of the compliance officer. Requirements set forth below apply to areas in 
which there is chloroform exposure.
Employers shall maintain records of environmental exposures to 
chloroform based upon the following sampling and recording schedules :
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(a) In all monitoring, samples representative of the exposure in 
the breathing zone of employees shall be collected. An adequate number of 
samples shall be collected to permit construction of a TWA exposure for 
workers in each operation or process. The minimum number of representative 
TWA exposure determinations for an operation or process shall be based o h  
the number of workers exposed as provided in Table 1-2 or as otherwise 
indicated by a professional industrial hygiene survey.
(b) The first environmental sampling shall be completed within 6 
months of the promulgation of a standard incorporating these recom­
mendations .
(c) Environmental samples shall be taken as soon as feasible but 
at least within 30 days after installation of a new process or process 
changes likely to cause an increase in environmental concentrations.
(d) Samples shall be collected at least quarterly in accordance 
with Appendix I for the evaluation of the work environment with respect to 
the recommended standard.
(e) Where exposure levels are found to be greater than those
prescribed in Section 1 (a), suitable control measures shall be initiated. 
Once controls are implemented, sampling should be resumed until it is
established that the controls are effective.
(f) All records of sampling and of medical examinations shall be 
maintained for at least 5 years after the individual's employment is 
terminated. Records shall indicate the type of personal protection 
devices, if any, in use at the time of sampling. Each worker shall be able 
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This report presents the criteria and the recommended standard based 
thereon which were prepared to meet the need for preventing occupational 
diseases arising from exposure to chloroform (CHC13). The criteria docu­
ment fulfills the responsibility of the Secretary of Health, Education, and 
Welfare, under Section 20(a)(3) of the Occupational Safety and Health Act 
of 1970 to "... develop criteria dealing with toxic materials and harmful 
physical agents and substances which will describe ... exposure levels at 
which no employee will suffer impaired health or functional capacities or 
diminished life expectancy as a result of his work experience."
The National Institute for Occupational Safety and Health, after a 
review of data and consultation with others, formalized a system for the 
development of criteria upon which standards can be established to protect 
the health of workers from exposure to hazardous chemical and physical 
agents. It should be pointed out that any recommended criteria for a
standard should enable management and labor to develop better engineering 
controls resulting in more healthful work practices and should not be used 
as a final goal.
These criteria for a standard for chloroform are part of a 
continuing series of criteria developed by NIOSH. The proposed standard 
applies only to the processing, manufacture, and use of chloroform as 
applicable under the Occupational Safety and Health Act of 1970.
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These criteria were developed to assure that the standard based 
thereon would (1) protect against development of acute and chronic effects 
from chloroform, (2) be measurable by techniques that are valid, 
reproducible, and available to industry and governmental agencies, and (3) 
be attainable with existing technology.
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III. BIOLOGIC EFFECTS OF EXPOSURE
Extent of Exposure
Chloroform (CHC13) is a nonflammable, clear, colorless, volatile 
liquid at ordinary temperature and pressure. It has a pleasant ether-like, 
nonirritating odor. [1] The more important physical properties are 
presented in Table X-l. [1-4]
Chloroform was originally made from acetone and bleaching powder and 
can also be made by reduction of carbon tetrachloride. The principal 
method of manufacture is now chlorination of methane. [1]
Prior to World War II, chloroform was used primarily as an
anesthetic and a pharmaceutical. The annual production of chloroform in 
the United States at that time was between 2,000,000 and 3,000,000 lbs. It 
is now seldom used as an anesthetic, [1] but it is used by many 
manufacturers for pharmaceutical purposes. [5,6] The production of 
chloroform for the manufacture of chlorodifluoromethane has grown over the 
years from 40,396,000 lbs in 1955 to 230,766,000 lbs in 1971, the latest
year for which data are available. [7-23]
In 1971, chloroform was manufactured by 6 chemical companies in the 
United States. Two of these companies and 3 others used chloroform in the 
manufacture of chlorodifluoromethane. [23]
NIOSH estimates that 80,000 people are potentially exposed to
chloroform in their working environment.
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Historical Reports
Simpson, [24] a surgeon and obstetrician in Edinburgh, reported in 
an 1847 issue of Lancet on the merits of chloroform as an anesthetic agent. 
He advocated its use because it was pleasant to inhale, its action was more 
rapid and complete than that of ether, only a small amount was needed to 
produce narcosis, and it did not require the use of a special inhaler or 
instrument for its administration. He especially recommended it for use in 
obstetric practice because it alleviated maternal pain and recovery from 
anesthesia was rapid.
In 1874, Witte [25] observed that it required less chloroform to 
anesthetize frogs by absorption through the skin of the abdomen or thigh 
than by inhalation. He reported that rabbits also could be anesthetized by 
application of chloroform to the shaved abdomen, and he recommended that 
humans be anesthetized by absorption through the skin rather than by 
inhalation.
One of the first detailed descriptions of death from liver damage 
following chloroform anesthesia published in the English literature 
appeared in the January 26, 1894 issue of Lancet. [26] A 4-year old boy 
seemed to be well after an operation which lasted about 1 hour, but early 
the next morning he began to vomit, his pulse became weak, breathing was 
shallow and irregular, and he lapsed into unconsciousness. Vomiting 
continued (the vomitus being dark brown in color), little urine was passed, 
consciousness was never regained, and death occurred 30 hours after the 
operation. At autopsy, the liver was found to be small (14 1/2 oz), pale 
buff color, studded with minute purple dots, and greasy to the touch.
17
Microscopy revealed intense fatty infiltration with no apparent fatty 
degeneration.
In 1898, Desgrez and Nicloux [27] reported that carbon monoxide was 
formed in dogs during chloroform anesthesia. They considered that the 
amount of carbon monoxide in the blood after 3-5 hours of anesthesia was 
equivalent to that present after exposure for 30 minutes to 100 ppm of 
carbon monoxide in air. Carbon monoxide was measured by a "grisoumeter" 
and chloroform did not interfere with the analytical method.
In 1904 Schwenkenbecher [28] reported that immersion of white mice
up to their necks in aqueous solutions of chloroform was lethal. The
solutions ranged from 0.3%-0.7% and the immersion time from 45-165 minutes. 
A special collar was used to preclude inhalation, and the genital and anal 
openings were closed.
Moore and Roaf [29] in 1906 reported that chloroform added to 
hemoglobin solutions at body temperature caused a change in color and a 
precipitation of the hemoglobin.
In 1909, Whipple and Sperry [30] published studies of liver necrosis 
in dogs following anesthesia with chloroform. They compared the liver 
damage observed in dogs to that seen in a 19-year old woman who died 3 days 
after anesthesia with chloroform for 35 minutes. They concluded that in 
dogs chloroform anesthesia for 1-2 hours would invariably cause central
liver necrosis, and that the anatomic changes in the human autopsy were
identical to those observed in the experimental dogs.
Lehmann [31] was the first to mention the industrial hygiene aspects 
of chloroform. He stated that in Germany more than 100 tons of chloroform
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was produced annually and that its manufacture in well designed factories 
did not create any danger to workers.
Lewin [32] in 1920 reported that the use of chloroform as a solvent 
for fats and resins was associated with a feeling of being "stoned", head­
ache, dizziness, breaking of the voice, sometimes an increase in saliva 
flow, bronchial catarrh, pounding of the heart, and with continued 
exposures, disturbances of metabolism, leading to a "real change in 
substance in the kidney and even to albumin in the urine."
Effects on Humans
(a) Central Nervous System Effects
The most outstanding effect of chloroform on the central nervous 
system is narcosis. Because of this property, chloroform was extensively 
used as an anesthetic. Featherstone [33] concluded from a review of the 
literature that 20,000 ppm of chloroform was usually used to produce 
anesthesia and that 40,000 ppm, if continued for several minutes, could be 
an overdose. He suggested, for induction of anesthesia, gradually 
increasing the concentration of chloroform during the first 2 or 3 minutes 
to attain and maintain a concentration of 25,000 or 30,000 ppm until full 
anesthesia developed. The concentration used to produce anesthesia is 
usually not maintained for the duration of the operation but is replaced by 
a lower maintenance concentration such that the integrated exposure was 
actually much lower than 20,000 ppm.
In the experiments reported by Lehmann and Hasegawa [34] in 1910, 
dizziness and light intoxication were experienced during 20-minute ex­
posures to chloroform concentrations of 4,300-5,100 ppm (20.8-25 mg/liter)
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(Table X-2). During exposure for 15 minutes to 7,200 ppm (35.3 mg/liter) 
(Table X-3), these effects became so pronounced that experimental exposure 
of humans to more concentrated chloroform atmospheres was deemed unsafe.
Lehmann and Schmidt-Kehl [35] reported human exposures to 10 con­
centrations of chloroform, all lower than those used by Lehmann and 
Hasegawa. [34] On 6 separate days they set up fans in a 10 x 10 x 10 meter 
"waterproof" room to evenly distribute chloroform spray from a dispersing 
apparatus with an oxygen bulb attached. The chloroform concentrations were 
determined by alkaline hydrolysis. [35] Other than odor there were no 
responses until a concentration of 920 ppm was achieved; exposure at this 
level for 7 minutes and at all higher levels up to 3,000 ppm caused 
symptoms of central nervous depression. Other symptoms including "headache 
and heart pounding" were observed at the highest levels.
Heilbrunn et al [36] tabulated 31 cases of "chronic chloroform 
poisoning" from the literature and recounted one case of a 33-year old male 
who habitually had inhaled chloroform for 12 years. The psychiatric and 
neurologic symptoms reported in this latter case were depression, loss of 
appetite, hallucinations, ataxia, and dysarthria.
Other symptoms from habitual use of chloroform such as moodiness, 
mental and physical sluggishness, nausea, rheumatic pain, and delirium are 
presented in Table X-4. These effects were reported from nonoccupational 
exposures. [36-40]
Three days after a 19-year old patient ingested an unknown amount of 
chloroform, Storms [41] noted cerebellar damage characterized by an 
instability of gait and a slight tremor on finger-to-nose testing. These 
signs disappeared in 2 weeks.
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Fokina [42] reported effects of chronic exposure in the work 
environment to mixtures of chlorinated methanes, including chloroform. 
Although the concentrations were not given, it was stated that the maximum 
permissible concentrations of individual components were exceeded at times. 
(There was no MAC for chloroform in Russia in 1965. [43] ) The majority of 
workers showed signs of autonomic dysfunction, including diminution or 
disappearance of the corneal reflexes, dissociation between the deep 
(exaggerated) and superficial (sluggish) reflexes, marked persistent 
dermographism, general hyperhydrosis, acrohyperhydrosis, blotchiness of the 
skin of the hand and forearms, tenderness when pressure was applied to 
specific cervical points, and arterial hypotension. Autonomic dysfunction 
was mainly found in workers employed for less than 3 years. Workers 
employed for more than 5 years showed diencephalic disturbances and 
autonomic polyneuritis. [42]
(b) Hepatotoxic Effects
Toxic effects of chloroform on the liver have been studied most 
often in conjunction with its use as an anesthetic, or in a few cases where 
a person either accidentally or intentionally ingested chloroform. Liver 
damage has been evaluated by liver function tests, and by macroscopic and 
microscopic observations.
Cullen et al [44] studied prothrombin in 6 patients before and after 
light to moderate chloroform anesthesia of 60-90 minutes' duration. 
Concentrations of chloroform in the blood were found to be 15-18 mg%. 
Prothrombin, determined by a 2-stage titration technique, was normal in all 
cases prior to operation and decreased in all cases following operation, by
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an average of 18% with a range of 11-40%. Icteric indices were markedly
elevated in 2 of the patients.
Elevated serum transaminase activity and prothrombin time were 
observed by Storms [41] in a 19-year old patient who had accidentally 
ingested an unknown amount of chloroform. The patient was comatose and 
cyanotic, breathing was labored, diastolic pressure reduced, pulse was 108, 
and there were decreased deep tendon reflexes. Liver function tests 
performed over a period of several days following ingestion are summarized 
in Table X-5. The values of all tests were normal 8 weeks after ingestion.
Delayed chloroform poisoning often occurred in obstetrical cases, 
[45-48] and many authors have described instances of this occurring after 
delivery. This delayed chloroform poisoning is usually characterized by a 
latent period of a few hours to a day before symptoms develop; then 
drowsiness, restlessness, jaundice, and vomiting may occur, followed by 
fever, elevated pulse rate, liver enlargement, abdominal tenderness, 
delirium, coma, and abnormal findings in liver and kidney function tests. 
Death often ensues, usually from 3-10 days post partum. Autopsy reports 
generally describe the liver as having a bright yellowish color, and on 
microscopy, fatty infiltration with necrosis.
Examples of delayed chloroform poisoning following obstetrical 
anesthesia in which vomiting, jaundice, delirium, coma, and sometimes death 
occurring are presented in Table X-6. Results of urine and blood analyses 
of 2 cases are presented in Table X-7. Gibberd [45] studied 3 women given 
chloroform prior to delivery, who died from acute diffuse necrosis of the 
liver. Each had received prenatal care by a physician and had apparently
been in normal health. Lunt [49] reported on 3 obstetrical exposures to
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chloroform from which all patients recovered. Obstetrical exposures, such 
as reported by Gibberd [45] and Lunt, [49] were generally multiple in 
nature, with the first chloroform concentrations administered to reduce 
pain but not to produce deep narcosis. Inhalations of chloroform from 
capsules or bottles were given for relief of pain at various intervals 
during labor, often separated by several hours. Furthermore, chloroform 
was often used as the anesthetic agent during delivery. Obstetrical 
patients were exposed to chloroform intermittently over long periods of 
time.
Surgical exposures differ from obstetrical exposures in that in the 
former there is usually an initial, high concentration great enough to 
produce unconsciousness, [48,50-53] followed by maintenance levels for the 
duration of the operation, usually lasting for 1/2 hour-2 hours.
Whipple and Sperry [30] recorded a fatal case of chloroform 
poisoning following a minor surgical procedure lasting only 35 minutes. 
Vomiting began the night after the operation and cramps developed on the 
following day. Muscle tremors, jaundice, and restlessness also developed. 
Three days after the operation the patient became comatose, his pulse rate 
and temperature increased and he died. Autopsy showed advanced central 
necrosis of the liver and fatty degeneration of the kidneys and heart.
Liver damage has also been reported following ingestion of chloro­
form. [52,54] Schroeder [52] described an acute case in which a man 
ingested 4 oz of chloroform. When first observed, his pupils were dilated, 
he was cyanotic and perspired profusely. An electrocardiographic tracing 
obtained a few hours after admission showed only occasional extrasystoles 
and minimal S-T depression. On the following day, there was no abnormality
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to be found in the tracing. He developed hepatomegaly with jaundice and 
vomiting. There were initial rises in serum bilirubin, alkaline
phosphatase, and SGOT. Recovery began on the fifth day after ingestion.
Bomski et al [55] reported enlarged livers in 17 of 68 workers 
exposed to chloroform in concentrations ranging up to 205 ppm. In 3 of the 
17 workers with enlargement of the liver, toxic hepatitis was diagnosed on 
the basis of elevated serum enzyme activities and elevated serum gamma 
globulin. In the remaining 14 cases of liver enlargement fatty liver was 
diagnosed, but not confirmed by liver biopsy.
(c) Renal Effects
Although the cause of death in most cases of chloroform poisoning 
has been attributed to necrosis of the liver, there has also been evidence 
at autopsy of renal damage, including albumin and red blood cells in urine, 
elevated blood urea, necrosis, and fatty degeneration. [30,45,49]
In the case of delayed chloroform poisoning reported by Whipple and
Sperry, [30] urine specimens contained a trace of albumin, a few hyaline 
casts, and considerable quantities of leucine and tyrosine. At autopsy, 
the convoluted tubules of the kidneys showed a definite fatty degeneration 
with some of the epithelial cells having undergone necrosis. The
capillaries were also found to be congested.
In the studies by Gibberd [45] and Lunt [49] laboratory findings 
indicated renal dysfunction; there were albumin, red blood cells, and pus 
in the urine, congestion of cortical vessels, fatty deposits, and necrosis.
(d) Cardiovascular Effects
Cardiac irregularities were found frequently by Kurtz et al [56] in 
1936 during electrocardiographic (ECG) surveillance of 113 surgical
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procedures. Arrhythmias were reported in all 6 cases in which chloroform 
was used for anesthesia and in 83 of 107 operations in which other anes­
thetics were used, including ethyl ether, cyclopropane, nitrous oxide, 
tribromoethanol, procaine, vinyl ether, and ethylene. The authors [56] did 
not report the durations of anesthesia.
In 1951, Orth et al [57] reported results of ECG surveillance during 
surgery on 52 patients given chloroform for' anesthesia. Among the 52 
patients, many developed more than one type of cardiac irregularity during 
anesthesia and 7 patients were symptom free. There were 4 instances of 
sinoauricular block, 11 of sinoauricular extrasystoles, 4 of auricular 
fibrillation, 22 of auriculoventricular block, 14 of auriculoventricular 
extrasystoles, 32 of auriculoventricular rhythm, 36 of ventricular extra­
systoles, 6 of slow ventricular rhythm, 2 of bundle branch block, 20 of 
ventricular tachycardia, and 4 cases of cardiac arrest. The authors [57] 
stated that "this is a higher incidence of irregularities than is observed 
clinically with any other anesthetic agent except trichloroethylene". The 
irregularities were attributed to both reflex effects on cardiac 
automaticity and a direct depressant effect on the myocardium. In view of 
the high incidence of ECG abnormalities with all studied anesthetics, [56] 
the possibility of all other factors in the etiology of the abnormalities 
needs to be considered in drawing conclusions from this study. For example 
Orth et al [57] did not report the durations of anesthesia while Whitaker 
and Jones [58] considered this to be important.
Whitaker and Jones [58] in 1965 found less frequent cardiovascular 
effects among 1,502 cases where chloroform was administered by a precision 
vaporizer in concentrations not exceeding 22,500 ppm. There were 9 cases
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of arrhythmia in the 1,164 operations in which anesthesia lasted 30 minutes 
or less and there were 10 cases of arrhythmia in 338 operations in which 
the duration of anesthesia was greater than 30 minutes.
(e) Hemolysis
Belfiore and Zimmerman [59] found that chloroform could affect the 
fragility of the red blood cell membrane without first being metabolized in 
the liver. Erythrocytes from 12 healthy adults were suspended in saline 
solution with chloroform ranging from 0.0125-0.10 mole/liter. The control 
was erythrocytes in a saline solution. At concentrations of 0.0125, 0.02, 
and 0.025 mole/liter there was no demonstrable effect. In concentrations 
of 0.05 mole/liter, erythrocyte leakage of hemoglobin, lactic dehydrogenase 
(LDH), and malic dehydrogenase began at 7 minutes and reached a maximum at 
20 minutes for hemoglobin and at 10 minutes for the enzymes.
Belfiore and Zimmerman [59] found that incubation of cells with 
reduced glutathione (GSH) and oxidized glutathione (GSSG) inhibited 
hemolysis as measured by a loss of hemoglobin. They found that inhibition 
increased as the concentration of GSSG increased, but did not increase as 
the concentration of GSH increased. It has been suggested more recently, 
however, that it is only the GSSG that enters the intact red blood cell; 
the effect of GSH is due to its oxidation to GSSG. [60]
(f) Effects on the Skin
Malten et al [61] measured injury and regeneration of forearm skin 
exposed to liquid industrial solvents, including chloroform. The solvents 
were contained in glass cylinders 2 cm in diameter which were fixed to the 
skin by agar-agar for 15 minutes a day for 6 consecutive days. An unspeci­
fied number of sites served as controls. The rate of water evaporation
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from these sites was determined daily to evaluate the degree of skin damage 
and regeneration. Exposure to chloroform was reported to be similar in 
effect to ethanol and to cause an increase in the rate of water evaporation 
with repeated exposures. Recovery of normal water retention, indicative of 
the formation of a new horny layer, occurred slowly during the 30 days 
after the last exposure.
Hoffman [62] suggested that chloroform could be used on skin to
combat mosquitoes and other biting insects. It seems doubtful that
present-day dermatologists would recommend this use of such an irritating 
substance. Hoffman cautioned against getting chloroform into eyes and
mucous membranes because of irritating effects.
Oettel [63] carried out systematic experiments with chloroform 
administered to the skin by way of a small glass vessel, 1 cm in diameter,
one end of which was open, with glass hooks fused into it. Vessels were
filled with chloroform and tied onto the arms of 5 subjects. Pure 
chloroform was used for various exposure times. Three minutes after 
application of chloroform, there was a sensation of burning and stinging. 
When exposure time was increased to 6 minutes, the pain became more intense 
and then subsided quickly. When the chloroform was removed, the pain
increased again, only to be replaced by a loss of feeling. Erythema was 
noted and the hyperemia which also occurred after 3 minutes of exposure was 
somewhat stronger, more cherry red with a light yellow undertone. In a 30- 
minute period after removal of the chloroform, there was a fading away of
the erythema and hyperemia, and 5 hours later, little blisters formed at
the edge of the area of application. Erythema and pigmentation disappeared 
7 days after the exposure.
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From these studies, [61-63] it can be concluded that exposure of the 
skin to liquid chloroform will cause irritation, erythema, hyperemia, and 
destruction of the epithelium. Much of this information on skin irritation 
from chloroform is based on prolonged contact. However, it should be noted 
that repeated, brief contact can cause skin defatting.
(g) Respiratory Absorption
Absorption of inhaled chloroform was studied by Lehmann and Hasegawa 
[34] in 1910. In a series of 3 experiments they computed the amount of 
chloroform absorbed as indicated by the difference between the concentra­
tions in the inhaled and exhaled air. Each subject inhaled chloroform
vapor through the mouth and exhaled air was collected in alcohol and
subsequently analyzed for chloroform by hydrolysis with alkali. In the 
first experiment one subject inhaled 3 different concentrations of
chloroform from a vessel containing a weighed amount of chloroform and the 
other inhaled 4 different concentrations. Each trial was performed at 
intervals of at least 3 hours. At exposure concentrations ranging from 
2,700-6,500 ppm and exposure times of 3-10 minutes, the percent absorption 
ranged from 54-73.
In the second experiment 2 subjects each inhaled chloroform for 20 
minutes on 3 separate days. The exposure concentrations were between 4,300 
and 5,000 ppm (20.8 and 25 mg/liter). The percentages of chloroform 
absorbed which ranged between 49.4 and 77 are presented in Table X-2.
In the third experiment one subject inhaled chloroform on 2
different occasions. The percentages of chloroform absorbed which ranged 
from 73.8-80.7 are presented in Table X-3.
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(h) Breath and Tissue Concentrations
Several investigators have measured the concentration of chloroform 
in exhaled air, blood, and other tissues, after inhalation or ingestion of 
chloroform. [34,41,44,50,64-66]
The concentrations of chloroform found in exhaled air by Lehmann and 
Hasegawa [34] after exposure were a function of the amount inhaled and the 
elapsed time after exposure (Table X-3).
In 1951, Morris [50] studied chloroform in exhaled air and 
peripheral venous blood of patients undergoing surgery. Exhaled breath 
samples from 11 patients maintained for various times in the third stage 
(surgical level) of chloroform anesthesia were collected in alcohol and 
evaluated by a modified Fujiwara reaction. The data are presented in Table 
X-8. The concentrations found were greater in plane 3 (deep surgical 
anesthesia) than in plane 1 or 2 (light or moderate surgical anesthesia) 
and they were greater at the beginning of anesthesia than at later times 
during anesthesia. Since chloroform is administered intermittently during 
surgery, the exhaled breath concentrations probably reflected time-weighted 
average exposure.
Peripheral venous blood was also collected from 58 patients when 
blood concentrations of chloroform necessary to maintain anesthesia were 
thought to have been achieved. Analysis was by ether extraction and a 
modified Fujiwara method. Chloroform concentrations of 2.0-23.2 mg % were 
found. Thirty to 50% of chloroform in the blood at the end of exposure was 
removed in the first 15 minutes following cessation of exposure. 
Thereafter, the rate of elimination decreased, and "small amounts" were 
reported to have been detected in the blood 8 hours after exposure.
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Concentrations of chloroform in the blood were also measured by 
Cullen et al [44] in 1940 in 3 persons undergoing surgery. Two patients 
were anesthetized by the absorption technique, with the inhaled gas con­
taining at least 50% oxygen. In one subject, 60 minutes after induction of 
anesthesia, chloroform was 16 mg %; in the other subject it was 18 mg % 70 
minutes after induction of anesthesia. In the third patient, anesthesia 
was induced by the open drop technique and then maintained by pharyngeal 
insufflation. In this patient, at 75 minutes of anesthesia, 15 mg % 
chloroform was found in the blood.
Storms [41] reported a case in which a 19-year old boy accidentally 
ingested an unknown amount of chloroform and was found to have 20 mg % of 
chloroform in the blood 10 hours after the ingestion. This case is 
reported in more detail in the section on hepatotoxicity.
Breath concentrations of chloroform in a worker after an industrial 
exposure to a mixture of solvents including chloroform, carbon 
tetrachloride, trichloroethylene, and perchlorethylene were measured by 
Stewart et al [64] in 1965. The exposure was defined as a "few minutes" 
without a gas mask followed by an unspecified time with a general purpose 
chemical respirator, to unknown concentrations with "strong" odors. The 
exposed worker experienced dizziness, weakness, nausea, and finally 
unconsciousness. The duration of unconsciousness is not known, but "10 
minutes later" he was coherent, though uncoordinated and nauseated. Thirty 
minutes after his collapse, infrared analysis of his expired breath 
contained: perchlorethylene, 11 ppm; carbon tetrachloride, 9.5 ppm;
chloroform, 7 ppm; and trichloroethylene, 11 ppm. Three days later, 0.1
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ppm chloroform was found in the exhaled breath; 12 days after exposure, 
there was no chloroform found in the exhaled breath.
Several authors have reported on the concentration of chloroform in 
tissues following suicide, homicide, or death during or after an operation. 
Gettler [65] measured brain concentrations of chloroform from 390-480 mg/kg 
in 4 cases of suicide by inhalation, 372-384 mg/kg in 3 cases of homicide 
by inhalation, and 70-182 mg/kg in 10 cases of death during or after 
surgery.
Gettler and Blume [66] used a modified Fujiwara method to estimate 
chloroform content of tissues following death during or after an operation, 
or by suicide or homicide. In 7 cases where death was reported to be due 
solely to excessive amounts of administered chloroform, concentrations in 
mg/kg tissue were: brain, 372-480; lungs, 355-485; and liver, 190-275. In
9 cases of death from shock, concentrations in mg/kg were: brain, 60-182
(most were between 120 and 182); lungs, 95-145; and liver, 65-88.
Epidemiologic Studies
There are very few reports of industrial workers exposed to 
chloroform. The studies of Challen et al [67] and Bomski et al [55] are 
the only studies that contain exposure concentration measurements, 
descriptions of symptoms and diagnoses, and comparisons with control 
groups.
In 1958, Challen et al [67] reported a study of a confectionery firm 
in England that manufactured medicinal lozenges. In 1950, the operators 
began to complain of the chloroform vapor given off during the production 
of the lozenges. A system of part-time work was initiated to alleviate
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complaints of lassitude, flatulence, water brash (British term indicative 
of symptoms of dyspepsia), dry mouth, thirst, depression, irritability, and 
frequent and "scalding" micturition, but this was not successful, and fi­
nally the operators refused to work on that particular process. In 1954, a 
new team of operators was engaged and in 1955 a system of exhaust ven­
tilation was installed, after which the work proceeded without interrup­
tion.
In order to confirm the effectiveness of the ventilation system, 
Challen and his associates [67] were asked to ascertain the concentrations 
of chloroform. Additionally, clinical investigations were performed and an 
attempt was made to simulate the original conditions in order to compare 
the chloroform concentrations before and after remedial measures were 
introduced. The original conditions were simulated by closing the doors 
and windows and shutting off the ventilation system.
A single air sample was taken continously in the breathing zone of 
the operator of the ingredient mixing process during a period of 20 minutes 
coinciding with the duration of the process. Sampling at the rate of 2 
liters/min was done by drawing air through 2 U tubes containing dried 
silica gel. Additionally, at a point in the operation where a peak 
concentration was expected, a 6-liter "grab" sample was taken. Air samples 
of 30-minute durations each were also taken in the breathing zones of 
cutting room operators. The samples were taken during 2 periods of 
production for 3 different operations on the same day (under current 
conditions) and during 3 periods on another day (during the simulated 
conditions). The samples were analyzed by alkaline hydrolysis. Results in 
ppm of chloroform were as follows [67]:
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Clinical investigations of 3 different groups of workers were per­
formed by Challen et al. [67] One group of 8 employees was termed the 
"long service operators". These were people who refused to continue in the 
lozenge department after they experienced the previously described 
symptoms. This group of workers, when exposed to chloroform vapor in 
probable concentrations ranging from 77 to 237 ppm, had been observed 
staggering about the work area. After terminating work in the lozenge 
department the "long service operators" reported experiencing nausea and 
stomach upset after even short exposures to the smell of chloroform.
A second group of 9 employees in this study, [67] termed the "short 
service operators", were the replacements of the "long service operators". 
Two of these 9 employees did not report unpleasant experiences from 
chloroform exposure. Among the other 7, 5 reported dryness of the mouth
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and throat at work; 2 were subject to lassitude in the evening; 1 
complained of lassitude and flatulence at work, and the experiences of 2 
others were similar to those of the "long service operators". The "short 
service operators" worked in locations where the chloroform concentrations 
ranged from 23-71 ppm.
A third group of 5 employees in this study [67] who worked in other 
departments of the firm served as controls and exhibited no symptoms. 
Neither tests of liver function (thymol turbidity, thymol flocculation, 
direct van den Bergh, and serum bilirubin), clinical examinations, nor 
urinary urobilinogen showed significant differences among the 3 groups of 
workers.
In 1967, Bomski et al [55] reported on liver injury from chloroform 
among workers in a pharmaceutical factory in Poland. The study included 
the entire group of 294 workers who used chloroform in the course of 
production; of these, 68 were exposed to chloroform for 1-4 years and still 
had contact with chloroform, 39 had chloroform contact at one time, 23 had 
viral hepatitis with icterus 2-3 years earlier and were designated as 
posticterus controls and were working in a germ-free area, and 165 worked 
in a germ-free area with no history of viral hepatitis. Blood pressure, 
blood morphology, urinalysis, blood albumin, serum protein, thymol 
turbidity, zinc sulfate turbidity, the "Takata-Ara" sulfate (colorimetric) 
test, urobilinogen, SGOT, and SGPT were measured in all. A complete 
medical history was taken. Sixty of the people were hospitalized for 
determination of BSP clearance and urinary urobilinogen.
The air in the production room was sampled and chloroform concentra­
tions were determined using the Grabowicz [68] method. The concentration
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of chloroform ranged from 2-205 ppm. No other concentration measurements 
were reported nor was there any mention of the frequency of sampling.
The authors [55] compared the frequency of viral hepatitis and 
jaundice among a group of inhabitants of the city, 18 years and older, with 
that of the same 68 pharmaceutical workers who used chloroform. The 
results showed that in 1960, 0.35% of city inhabitants had viral hepatitis, 
while 16.67% of the chloroform exposed workers had viral hepatitis. In 
1961, the frequency for city inhabitants was 0.22% and the frequency among 
the chloroform workers was 7.50%. In 1962 the frequency of viral hepatitis 
was 0.38% for city inhabitants and 4.4% for workers using chloroform. The 
authors suspected that the toxic liver changes occurring as a result of 
exposure to chloroform promoted a viral infection in such cases, but they 
did not give information on the incidence of viral hepatitis among other 
plant workers, which might have helped resolve questions about sanitary 
practices and facilities in the plant.
The majority of the workers who were in contact with chloroform 
during the investigation period covered in this study complained of 
headache, nausea, belching, and loss of appetite.
Among the 68 workers using chloroform, 10 cases of splenomegaly were 
found compared to none in the controls. They did not explain the 
splenomegaly but point out it was not present in controls.
The frequency of enlarged livers (17 out of 68) among workers 
exposed to chloroform exceeded the frequency of enlarged livers in the 
other groups (5 out of 39, and 2 out of 23). Livers were judged to be 
enlarged if they extended at least 1 cm beyond the rib arch in the 
midclavicular line. The upper margin was apparently not measured. In 3 of
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the 17 chloroform workers with enlargement of the liver, toxic hepatitis 
was diagnosed on the basis of elevated serum enzyme activities and elevated 
serum gamma globulin. The measured amounts of these serum constituents in 
these 3 workers were not reported. In the remaining 14 cases of liver 
enlargement, fatty liver was diagnosed. It was claimed that the latter 
diagnoses were substantiated by a 79% reduction in the incidence of 
hepatomegaly in the people studied during a 12-month period when hygienic 
work conditions were improved as a consequence of the studies. [55]
In a continuing study [LD Pagnotto, written communication, December 
1973] by the Department of Labor and Industries, Commonwealth of 
Massachusetts, worker exposure to chloroform, methylene chloride, and 
toluene in a plant manufacturing plastic film was investigated. The 
workers were exposed to levels of chloroform from 7-170 ppm, with a mean of 
47 ppm.
Physical examinations and the following laboratory tests were 
performed regularly on all employees connected with the process: SGOT,
LDH, alkaline phosphatase, blood bilirubin, BUN, creatinine, cholesterol, 
serum protein, urobilin, urobilinogen, urine bilirubin.
The blood tests were performed yearly and urine tests quarterly. 
The liver function tests have been done for more than 2 years, the kidney 
function tests for only 1 year. Some of the employees at times experienced 
what was termed "dry heaves". Laboratory findings have been normal so far, 
but there appeared to be a significant number of findings in the upper 
normal range, particularly for the blood bilirubin and BUN. There was no 
evidence, though, that there was a progressive increase in the values 
found. However, the evaluations of the laboratory findings were based on
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the normal range for the general population rather than a specific control 
group for this particular investigation.
It is not apparent from this study what the time-weighted average 
exposures were.
Animal Toxicity
The majority of animal studies of chloroform toxicity have been con­
ducted to provide supplementary information relevant to the clinical use of 
chloroform as an anesthetic. Consequently these animal studies include 
concentrations of chloroform many times greater than would be experienced 
in daily occupational situations except in the case of accidents. The 
following subsection contains a summation of some of these studies.
(a) Central Nervous System Effects
Chloroform has been reported to cause narcosis in a variety of 
experimental animals. [69-72] Fuhner [71] exposed 30 mice to vapor 
concentrations of chloroform ranging from 2,500-7,400 ppm (12-36 mg/liter). 
Each mouse was individually exposed in 10- to 11-liter bottles with the 
chloroform vaporized to the concentration desired. The method of 
ascertaining the concentration was not stated. The following effects were 
observed:
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2,500-2,700 ppm (12-13 mg/liter) - some loss of reflexes, rarely
narcosis, recovery in 2 hours
4.000 ppm (20 mg/liter) - narcosis in 1 hour and recovery 
4,700-6,000 ppm (23-27 mg/liter) - narcosis in 3/4 hour,
recovered, some died 
6,800 ppm (33 mg/liter) - narcosis in 1/2 hours, death in most
7,400 ppm (36 mg/liter) - narcosis in 10 minutes
In 1936 Lehmann and Schmidt-Kehl [35] studied the acute effects of 
chloroform on cats. Fully grown cats weighing 2.5-3.5 kg were fasted 
before the experiment then exposed to concentrations ranging from 7,200-
22.000 ppm (35-105 mg/liter). The concentrations of chloroform were 
determined by hydrolysis with alkali in alcohol. Upon exposure to 
chloroform, toppling, loss of righting ability, and loss of leg reflexes 
were observed. At 7,200 ppm (35 mg/liter) light narcosis was observed at 
78 minutes and deep narcosis after 93 minutes. Exposure to 22,000 ppm (105 
mg/liter) brought about light narcosis after 10 minutes and deep narcosis 
after 13 minutes. Depression of nervous and muscular activity was 
accompanied by irritation of the mucous membranes of the eyes, nose, and 
mouth.
Lehmann and Hasegawa [34] studied absorption of inhaled chloroform 
in rats exposed to concentrations of 4,100, 4,300, 11,000, and 16,400 ppm 
(20, 21, 54 and 80 mg/liter) for 4, 12, 10, and 10 hours, respectively.
Concentrations of chloroform were determined by hydrolysis with alkali in 
alcohol. At a concentration of 4,000 ppm (20 mg/liter), 30.6% of the 
chloroform inhaled during the first 15 minutes was absorbed, 25.4% after
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the first hour, and so forth, decreasing to a minimum of 4.8% after 4 
hours. Concentrations of 11,000 and 16,400 ppm (54 and 80 mg/liter) si­
milarly showed absorption decreasing with time of exposure. The initial 
absorption was never greater than 40%.
(b) Hepatotoxicity
Numerous studies have shown that chloroform causes fatty 
infiltration and necrosis of the liver. [30,73-77] None of these studies 
involved long-term inhalation exposures to low concentrations. However, 
these studies do show that the hepatotoxic effects of chloroform can occur 
as the result of ingestion, inhalation, or intravenous administration.
Whipple and Sperry [30] pointed out the similarity of microscopic 
changes in the livers of humans and experimental animals including fatty 
degeneration and centrilobular necrosis. They administered 1-2 oz of 
chloroform for 1-2 hours (implying inhalation) to dogs, often on successive 
days. In general, the animals recovered from the anesthesia and initially 
appeared to be quite well. However, vomiting began to occur (sometimes 
with blood) 1-4 days after exposure to chloroform and some of the animals 
developed diarrhea. Death then ensued. Autopsies revealed lesions of the 
liver, including central hyaline necrosis, acute yellow atrophy, and 
subcapsular hemorrhage. Less frequently the kidneys showed fatty 
degeneration of the convoluted tubules. Where death due to chloroform did 
not occur, liver repair was noted within 7-12 days.
Jones et al [74] in 1958 studied the relative hepatotoxicity of 
inhalation anesthetic drugs using chloroform as a standard of reference. 
Chloroform was given orally to 350 white mice, each weighing approximately 
20 g. The mice were killed 72 hours after exposure and livers were fixed
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in formalin. The authors [74] were able to estimate the following effects 
of acute injury from esophageal instillation of chloroform:
0.35 mg/g minimum narcotic dose (MND 50)
1.1 mg/g minimum lethal dose (MLD 50)
0.035 mg/g threshold hepatotoxic effect- minimal midzonal fatty changes
0.07 mg/g minimal central fatty change - fatty infiltration
0.14 mg/g moderate liver changes - massive fatty infiltration
0.35 mg/g severe liver changes - fatty infiltration, centrilobular necrosis
Kylin et al [78] in 1963 studied the hepatotoxic effects of inha­
lation exposure of 20 mice to chloroform for 4 hours. The experiments were
performed on female albino mice, of a single strain, with a mean weight of 
23 g. The mice were exposed to chloroform concentrations of 100, 200, 400, 
or 800 ppm for 4 hours in a chamber approximately 15 liters in volume. The 
mice were killed 1 or 3 days after exposure and tissues studied micro­
scopically. Evaluation was limited to assessing the extent of necrosis and 
the degree of fat infiltration of the liver. Mice exposed to 100 ppm for 4 
hours and killed 1 or 3 days later showed moderate infiltration of fat in 
the liver. Specifically, the liver underwent fatty degeneration involving 
a thin cell layer, usually in the periphery of the liver lobules, and up to
3 to 5 cell-widths in size. These alterations were seen more frequently in
mice killed 1 day after exposure than in those sacrificed after 3 days. 
Exposure of mice to 200, 400, or 800 ppm caused increased liver alteration 
including some necrosis at 200 ppm, increasing in extent at 400 and 800
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ppm. Associated with the microscopically demonstrable liver necrosis was 
the increase in activity of serum ornithine-carbamoyl transferase.
(c) Nephrotoxicity
Kidney involvement as a result of exposure to chloroform was 
reported as early as 1929 by Whipple and Sperry. [30] Dogs inhaling 1-2 oz 
chloroform during 1-2 hours often showed on successive days fatty 
degeneration of the convoluted tubules of the kidneys.
Plaa and Larson [79] in 1964 studied the nephrotoxic properties of 
chlorinated hydrocarbons in mice. In assessing kidney function, phenol- 
sulfonphthalein (PSP) excretion and urinary protein and urinary glucose 
were measured. The chlorinated hydrocarbons were dissolved in corn oil and 
the doses administered intraperitoneally in 10 ml corn oil/kg body weight. 
In mice treated with chloroform the effect on the kidney, as measured by 
decreases in PSP excretion 24 hours later, was dose-dependent. The 
presence of any glucose or 100 mg % of protein 24 hours after 
administration, or less than 40% PSP excretion in 2 hours, was considered 
significant and indicative of impaired renal function. The extent of 
kidney impairment, expressed in terms of the 3 function tests, increased 
with the dose of chloroform. The incidence of reduced PSP excretion in 2 
hours decreased as the dose of chloroform decreased from 1 ml/kg-0.016 
ml/kg. With a 0.5 ml/kg dose of chloroform, PSP excretion although 
initially reduced, returned to normal after 4 days. Tables X-9 and X-10 
show the relationship of the 3 variables studied to the chloroform dosage.
Microscopic examination of kidney sections showed correlation 
between the percentage of mice in each group showing abnormal kidney 
function tests and the percentage showing necrosis of the proximal tubules.
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The median effective dose of chloroform (ED50) for significant PSP 
excretion was 0.12 ml/kg and for increasing urinary protein and glucose, it 
was 0.07 ml/kg. [79]
Of all the chlorinated hydrocarbons tested, chloroform and 1,1,2- 
trichloroethane possessed the most marked nephrotoxic properties, causing 
proteinuria and glucosuria with nonlethal doses and a decrease of PSP 
excretion, and necrosis of the convoluted tubules in 100% of the animals at 
higher doses. [79]
(d) Chronic Ingestion Study
The study by Miklashevskii et al [80] exposed 18 male albino rats 
with an initial weight of 150-180 g, and 18 male guinea pigs with an 
initial weight of 220-250 g; they were divided into 3 groups of 6 animals 
of each species. Animals of the first group received a peroral chloroform 
dose of 0.4 mg/kg. In the second group, the guinea pigs received a dose of 
35 mg/kg (1/50 LD50), while the albino rats received a dose of 125 mg/kg 
(1/50 LD50). The third group served as a control. No mention was made of
the dosing schedule although the experiment ran for 5 months and daily 
administration was implied.
Rats and guinea pigs given the 0.4 mg/kg dose of chloroform showed 
no changes in conditioned reflexes or in autonomic or cardiac activity, 
blood protein ratios, catalase concentrations, or phagocytic capacity. 
There was an increase in ascorbic acid in the adrenals of the guinea pigs. 
[80]
Some guinea pigs given doses of 35 mg/kg died during the course of 
the experiment. Five of the guinea pigs lived longer than 2 months, but 
only 2 of these lived longer than 3 months. The ratio of blood protein
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fractions in the guinea pigs given 35 mg/kg was altered by the end of the 
first month. These changes consisted of an increase in the globulin 
content (from 32.9±1.09 to 40.9±2.22%) involving the alpha and gamma 
fractions and a decrease in the albumin content, so that the albumin-glo- 
bulin ratio decreased from 2.1-0.4. The change in this ratio was even more 
pronounced at the end of the second month. The guinea pigs in the 35 mg/kg 
groups also showed a decrease in blood catalase activity from 2.0±0.13- 
1.2±0.11 (no units given) in the second month of the experiment. [80]
The guinea pigs which had died from a dose of 35 mg/kg of chloroform 
had structural lesions of the liver, heart muscle, and stomach wall upon 
microscopic examination. Microscopic changes included fatty infiltration, 
necrosis and cirrhosis of the liver parenchyma, lipoid degeneration, pro­
liferation of interstitial cells in the myocardium and acute edema of the 
submucosal and muscular layers of the stomach. [80]
The rats of the group that received doses of 125 mg/kg showed no 
significant changes in the conditioned reflexes after one month, but during 
the fourth and fifth month, ability to develop new conditioned reflexes was 
impaired.
Studies of the autonomic regulation of cardiac activity indicated a 
decrease in cholinergic activity. [80]
(e) Carcinogenicity
Eschenbrenner [81] in 1945 studied the effect of repeated oral doses 
of chloroform on induction of hepatomas in mice. This study followed the 
format of an additional study by the same author that showed induction of 
hepatomas by repeated feeding of carbon tetrachloride in olive oil 
solution, in amounts sufficient to produce liver necrosis. [82]
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Accordingly, a graded series of necrotizing and nonnecrotizing doses of 
chloroform were administered. Three-month-old strain A mice which had an 
incidence of spontaneous hepatomas of less than 1% at 16 months were given 
intragastric doses of oil solutions of 5 /¿1/kg body weight. The chloroform 
content of the solutions varied so that the chloroform doses were 
respectively 1.6, 0.8, 0.4, 0.2, or 0.1 ¿il/kg.
The presence or absence of liver necrosis was determined by micros­
copic examination of liver sections taken 24 hours after a single dose of 
chloroform. The livers of animals receiving doses of 0.2 and 0.1 jul/kg of 
chloroform showed no necrosis. However, with these doses, necrotic areas 
were observed in the kidneys of males, but not of females. This sex dif­
ference of renal necrotic lesions was observed at all concentrations. No 
sex difference was observed for liver necrosis. Twenty-four hours after a 
single dose of 0.4 Ml/kg or more of chloroform there was extensive necrosis 
of liver cells around the central veins. Thirty doses were given at 4-day 
intervals to test for any carcinogenic effect. (This was the schedule 
under which a hepatoma incidence of 100% was obtained when carbon 
tetrachloride was used.) Hepatomas were found only in animals that 
received necrotizing doses of chloroform and which were killed 1 month 
after the last dose. [81] These were seen only in female mice, which could 
reflect the greater sensitivity of males, ie the males might have died 
earlier, before onset of malignant changes. The authors inferred that 
necrosis was a prerequisite to tumor induction. The significance of this 
study on occupational exposures is not clear; more studies to clarify 
questions of carcinogenicity of chloroform need to be conducted.
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(f) Teratogenicity
Schwetz et al [83] in 1973 evaluated the effects of repeated ex­
posures to chloroform on rat embryo and fetal development. Pregnant 
Sprague-Dawley rats were exposed to 30, 100, or 300 ppm of chloroform for 7 
hours a day on days 6 through 15 of gestation. Day 0 of pregnancy was con­
sidered to be the day on which sperm were seen in vaginal smears. Con­
centrations of chloroform in the exposure chambers were continuously moni­
tored by combustion analysis. An infrared spectrophotometer with a multi- 
path gas cell was used 3 times daily to analyze the chamber air and sub­
stantiate the concentration calculations.
The effect of chloroform on rats exposed to 300 ppm was confused by 
changes in dietary intake. It was not possible to determine whether 
decreased food consumption was the result of loss of appetite or the 
inability to eat due to narcosis. [83]
Exposure of pregnant rats to 100 ppm on days 6 through 15 of 
gestation revealed a significant incidence of fetal abnormalities as 
compared to controls. There were significant increased incidences of 
acaudia, imperforate anus, subcutaneous edema, missing ribs, and delayed 
skull ossification.
Rats exposed to 30 ppm showed significant incidences of delayed 
skull ossification and wavy ribs, but no other effects. [83]
The teratogenicity of oral doses of chloroform was studied in rats 
and rabbits. [84] There was no evidence of teratogenicity in either species 
at any dosage level tested. However, in both species reduced birth weights 
(7.5% in rats and 1.1% in rabbits) were observed with the highest dosages, 
126 and 50 mg/kg, respectively.
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(g) Metabolism and Mechanism of Action
In 1961, Butler [85] demonstrated that chloroform is found in the 
expired air from dogs receiving carbon tetrachloride and that this conver­
sion can be reproduced by the incubation of carbon tetrachloride with 
tissue homogenates or with reduced glutathione or with cysteine. When 
chloroform was incubated for a day with homogenates of mouse liver, 
chromatograms revealed the presence of methylene chloride in concentrations 
of 30-90 jug/ml. However, no methylene chloride was found in the expired 
air of dogs receiving chloroform by inhalation.
Paul and Rubinstein, [86] in 1963, studied the metabolism by rats of
carbon 14 labeled carbon tetrachloride and chloroform. With intraduodenal 
doses of 1 ml/kg, some carbon tetrachloride was converted to chloroform. 
There was no evidence that other chloromethanes were formed from either
administered carbon tetrachloride or administered chloroform. Eighteen 
hours after dosing, 74% of the radioactivity from chloroform had appeared 
in the exhaled air as chloroform and 3.6% as carbon dioxide. More carbon 
dioxide was formed from chloroform than from carbon tetrachloride, both in 
vivo and in vitro, but never more than 5% of the administered chlorinated 
hydrocarbon was metabolized to carbon dioxide. Homogenation of the liver 
markedly diminished carbon dioxide production from both carbon
tetrachloride and chloroform.
The mechanisms of the biochemical effects of chloroform on the liver 
were studied by Scholler [87] and Reynolds and Yee. [88] Scholler [87] 
tried to determine whether structural damage affecting protein synthesis 
occurs when chloroform acts on the liver of a rat. Twenty Sprague-Dawley 
rats were fasted for 10 hours and 4 were exposed to 1 vol % chloroform
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Preliminary examinations of all animals anesthetized showed a slight 
increase in respiratory acidosis but no signs of arterial hypoxemia or 
metabolic acidosis. After 4 1/2 hours of chloroform anesthesia, the livers 
of most exposed rats showed gross enlargement of the centrilobular hepatic 
cells. The cells also showed a striking paleness, and upon staining of 
frozen sections, fatty degeneration was also observed. On electron
microscopy it was found that chloroform produced an early dilation of the 
granular endoplasmic reticulum with detachment of the ribosomes producing a 
marked reduction of centrilobular protein synthesis. Additionally, after 
anesthesia with chloroform, extensive necrosis of portions of the renal 
tubular epithelium was found, while the lung revealed severe leucocytic 
infiltrations in the alveolar septa. In light of this latter finding, it 
should be noted that in 1966 Wattenberg [89] stated that kidney and lung 
tissue also contain hydroxylating enzyme systems. This enzymatic activity 
is less intense than in the liver, but can be increased by some lipid- 
soluble compounds. Scholler [87] concluded that the toxic effect of 
chloroform on the liver, kidney, and lung as observed in animal experiments 
and in humans can be explained by the formation of toxic metabolites by 
hydroxylating enzyme systems in the cells of damaged organs.
Reynolds and Yee in 1967 [88] compared the patterns of incorporation 
of isotopic carbon from chloroform, carbon tetrachloride, methylene 
chloride, and methyl chloride into chemical constituents of liver organ­
elles 2 hours after oral introduction of the chloromethanes. This in­
vestigation was based on the hypothesis that the hepatotoxicity of the
compounds was related to the binding of reduction products of the chemical
(10,000 ppm) for a period of up to 5 hours in an anesthesia chamber.
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components to the endoplasmic reticulum and to the formation of 
chloromethylated lipids and proteins. They used 2 indicators of early 
damage to the endoplasmic reticulum: 1) The ability to suppress glucose-6-
phosphatase activity in the centrilobular portion of the liver in 1 hour; 
and 2) the ability to cause increases in cellular ribonucleic acid (RNA) 
content 2 hours after exposure. These indicators were compared with 
labeling of cellular constituents and with the ability of these agents to 
cause centrilobular necrosis 24 hours after exposure.
In the experiment, young male rats weighing between 100 and 300 g 
each were fed doses of either 830 or 2,600 /xmoles of chloromethanes per 100 
g of rat weight in an equal volume of mineral oil, by polyethylene stomach 
tube. Control animals received an equal volume of mineral oil. Animals 
were killed 1, 2, and 24 hours after dosing. Radioactive carbon
incorporation from labeled chloroform, carbon tetrachloride, methylene
chloride, or methyl chloride dissolved in 0.24 ml of mineral oil and fed to
animals after a fast of 16 hours was studied. Control animals received 
either labeled sodium bicarbonate in 0.5 ml of 0.01 N NaOH or labeled 
formaldehyde in 0.25 ml of water. Bicarbonate and formaldehyde are 
chloromethane oxidation products and these served as comparisons to the 
incorporation patterns of the 4 agents used. [88]
Two hours after oral introduction both carbon tetrachloride and, to 
a lesser extent, chloroform caused an increase in RNA content of the liver
and centrilobular necrosis at 24 hours. The concentrations of chloroform
found in the liver within the first few hours after dosing were slightly 
greater than those of carbon tetrachloride. However, the extent of 
necrosis from chloroform was less. The carbon labeled chloroform was re­
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covered in an amino acid locus corresponding to methionine. The amount of 
labeled radioactive carbon found in lipids and microsomes was related to 
the chlorine content of the chloromethanes.
(h) Potentiation
Alcohols, barbiturates, and some other chemicals such as DDT when 
administered before chloroform increase the toxic effects of chloroform, 
apparently by lowering the threshold for its necrotic action. [90-93]
Kutob and Plaa [90] found that ethanol pretreatment of mice in­
creased the toxic effect of chloroform on the liver. Male Swiss albino 
mice weighing 20-30 g were initially treated with an oral dose of ethanol 
(5 g/kg) in a 25% aqueous solution. The ethanol pretreatment was followed 
by single, subcutaneous, minimally hepatotoxic doses of chloroform (0.08 
ml/kg) given in a 1.6% olive oil solution. Time interval between ethanol 
pretreatment and dosing with chloroform was systematically shortened from 
15 days to 12 hours to determine the shortest period before administration 
of chloroform in which administration of ethanol would increase the 
susceptibility to chloroform. The time lag between ethanol and chloroform 
was purposely chosen so that the ethanol would be metabolized by the time 
the chloroform was administered. Each experiment consisted of 4 groups of 
animals: 1) untreated; 2) treated with ethanol; 3) treated with
chloroform; and 4) treated with ethanol followed by chloroform. Liver 
function was studied 24 hours after the administration of chloroform by 
determining 1) pentobarbital (45 mg/kg) sleeping time, 2) BSP retention, 
and 3) liver succinic dehydrogenase activity. Tissue slides were also 
studied to corroborate the liver function tests.
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All experiments showed reduced liver function as indicated by 
prolonged pentobarbital sleeping times and elevated BSP retention. The 
liver succinic dehydrogenase activity was depressed when chloroform was 
administered 12 or 24 hours after ethanol, but not when it was administered 
48 hours after ethanol. Ethanol alone or chloroform alone did not 
significantly depress succinic dehydrogenase activity.
In mice pretreated with ethanol 15 hours, or 1, 2, or 4 days before 
the administration of chloroform, microscopic examination revealed livers 
with cytoplasmic vacuolization in pericentral cells. The pericentral cells 
were also enlarged and almost completely devoid of eosinophilic material. 
[90]
In a similar study, Sipes et al [91] pretreated rats with isopro­
panol and reported enhanced ability to covalently bind radioactive carbon 
labeled chloroform to microsomal protein.
Dingell and Heimberg [92] studied the hepatic metabolism of amino- 
pyrine and hexobarbital in rat liver microsomes after the administration of 
chloroform or carbon tetrachloride or methylene chloride. The chlorinated 
hydrocarbons were administered in equimolar doses by gastric intubations 
and killed 24 hours later. Liver microsomes were prepared from rat livers 
weighing from 250-375 mg. Either 5 jumoles of aminopyrine or 1.9 /imoles of 
hexobarbital was added to a mixture of enzyme substrates.
The rate of metabolism of hexobarbital was measured by estimation of 
the disappearance of substrate. The rate of déméthylation of aminopyrine 
was measured by estimation of the amount of formaldehyde formed. For both 
the aminopyrine and hexobarbital pretreatment before carbon tetrachloride 
decreased the rate of metabolism significantly to 14 and 29%, respectively,
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of control values. Chloroform, however, only decreased metabolism of 
aminopyrine to 61% and hexobarbital to 95% of control values.
McLean [93] fed male mice either stock diet or protein free diets 
for 1 week before intragastric administration of chloroform. Some of the 
mice of each group were also given sodium phénobarbital in the drinking 
water (1 mg/ml) for 1 week before chloroform administration; others were 
given a single subcutaneous injection of DDT (100 mg/kg) 1 week before 
chloroform. The purpose of DDT and the phénobarbital administration was to 
stimulate liver hydroxylating enzyme activity. The purpose of the protein 
deficient diet was to reduce the liver hydroxylating enzyme activity, but 
in this experiment this was not realized. Phénobarbital and DDT increased 
the liver hydroxylating enzyme activity and the toxicity of chloroform was 
more than doubled by the phénobarbital and DDT pretreatment as measured by 
the LD50.
Correlation of Exposure and Effect
The use of chloroform as an anesthetic agent has provided 
information about the effects to be expected from acute exposure. 
Exposures during anesthesia have usually been to concentrations of around
20,000 ppm, [58] and exposure times have been from 30-240 minutes. 
[30,45,94] One or 2 days after chloroform anesthesia, nausea, jaundice,
and vomiting may develop, often followed by elevated temperature and pulse, 
epigastric pain, muscle twitching, delirium, and coma. In some cases, 
death has occurred 3-10 days after anesthesia. [30,45,46,51] Autopsies 
have demonstrated fatty infiltration of the liver with diffuse central 
necrosis, and enlarged, soft, congested kidneys with cloudy swelling of the
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epithelial lining of the convoluted tubules, and yellow striations marking 
the pyramids. [24,45,51,54,94]
Habitual inhalation of 1 oz daily of chloroform for 7 years followed 
by 2 oz/day for 5 more years was associated with delusions, restlessness, 
depression, convulsions, ataxia, dysarthria, tremor of the tongue and fin­
gers, and insomnia; at autopsy, the brain showed slightly thickened menin­
ges in the frontal lobe, many fibroblasts and dilated blood vessels. [36] 
In other cases of habitual chloroform inhalation for periods of time 
ranging up to 30 years, hallucinations, delirium, and tremors were common 
manifestations. [36] The exposures (Table X-4) are difficult to evaluate, 
but they were chronic and the effects on the central nervous system were 
definite.
Lehmann and Hasegawa [34] and Lehmann and Schmidt-Kehl [35] 
performed the only controlled exposure experiments with humans. The 
exposures were for a maximum of 30 minutes, and response measurements were 
limited to subjective responses of the subjects. These experiments provide 
information about responses of people exposed to 160 ppm (0.8 mg/liter or 
800 mg/cu m) through a range of concentrations up to 7,200 ppm (35.3 
mg/liter), as follows:
160 ppm (0.8 mg/liter) for unspecified time - no odor
205 ppm (1.0 mg/liter) for unspecified time - light transient odor
390 ppm (1.9 mg/liter) for 30 minutes - light transient odor
920 ppm (4.5 mg/liter) for 7 minutes - stronger, lasting odor; dizziness,
vertigo after 3 minutes
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680 ppm (3.3 mg/liter) to 1,000 ppm (5.0 mg/liter) for 30 minutes - 
moderately strong odor; taste
1.100 ppm (5.4 mg/liter) for 5 minutes - still stronger, permanent odor;
dizziness, vertigo after 2 minutes
1,400 ppm (6.6 mg/liter) to 1,800 ppm (8.57 mg/liter) for 30 minutes - 
stronger odor, tiredness, salivation, giddiness, vertigo, 
headache, taste
3,000 ppm (14.46 mg/liter) for 30 minutes - all above plus pounding 
heart, gagging
4,300 ppm (20.8 mg/liter) to 5,000 ppm (25 mg/liter) for 20 minutes - 
dizziness and light intoxication
5.100 ppm (25 mg/liter) for 20 minutes - dizziness and light intoxication
7,200 ppm (35.3 mg/liter) for 15 minutes - dizziness and light intoxication
as above but more pronounced
The data presented by Challen et al [67] provide some quantitative 
information about exposure and effect, even though some of the information 
about exposure was obtained after the fact. Employees in a confectionery 
manufacturing medicinal lozenges had complained of nausea, flatulence, loss 
of appetite, frequent and burning micturition, lack of mental 
concentration, depression, and irritability. Measurements were made of an 
atmosphere created under conditions which were considered to simulate those 
in existence at the time the employees were affected. The average 
chloroform concentrations based on 30-minute samples ranged from 77-237 
ppm. It was noted that reducing work to part time in this environment re­
lieved the employees ' complaints. No studies were made on the exposed
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workers during the time of the exposure which covered the years 1950-1954. 
Measurements of liver and kidney function made in 1958, 3-4 years after the 
exposure, were normal.
Another group of 10 workers were later engaged in the same jobs 
after ventilation was improved. These workers had been working 4 hours a 
day for 10-24 months under conditions where 30-minute average chloroform 
concentrations ranged from 23-71 ppm, except for 1 operation which ran 4 
times a day for a total of about 2 hours in which the exposure during 
operation averaged 128 ppm, with 4 exposures each lasting 1 1/2-2 minutes
at 1163 ppm.
In 9 of the latter workmen studied by Challen et al, [67] only 2 did
not report unpleasant experiences. Among the other 7, 5 reported dryness
of the mouth and throat at work; 2 were subject to lassitude in the
evening; 1 complained of lassitude and flatulence at work; and the 
complaints of 2 others were similar to those experienced by the original 
workmen. Liver function tests were normal in these workers.
In the study of Bomski et al, [55] workroom concentrations of
chloroform in a pharmaceutical industry fluctuated between 2 and 205 ppm, 
but no further information about environmental exposure concentrations was 
given. The incidence of viral hepatitis (4.4-16.7%) was much higher among 
the people working in the chloroform environment than among the general 
population (0.22-0.35%); and 10 cases of splenomegaly and 17 cases of 
enlarged liver were found among the 68 chloroform workers.
Sixty-eight workers who had been exposed to this chloroform environ­
ment for 1-4 years were studied in detail, along with 3 control groups: 1)
30 previously chloroform-exposed workers; 2) 23 nonchloroform exposed-
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workers who had previously had viral hepatitis; and 3) 165 nonchloroform
exposed workers with no history of viral hepatitis. Seventeen of the 68 
chloroform-exposed workers had enlarged livers. Three of these 17 workers 
had toxic hepatitis on the basis of elevated serum enzyme activities and 
elevated serum gamma globulin. The other 14 workers with enlarged livers 
were judged to have fatty liver, though admittedly without confirmation by 
biopsy.
The incidence of enlarged livers among these 68 workers was sig­
nificantly higher than in the controls. It was noted that there was a 
reduction in hepatomegaly in 79% of the people studied during the 6-12 
month period when hygienic conditions at work were improved. [55]
Schwetz et al [83] studied the effects of 30, 100, and 300 ppm of 
chloroform on pregnant rats for 7 hours/day on days 6 through 15 of 
gestation. There were significant incidence of delayed skull ossification 
and "wavy ribs" in litters from dams exposed to 30 ppm of chloroform.
The authors [83] found that in litters from dams exposed to 100 ppm 
there were significant incidences of acaudia, imperforate anus, 
subcutaneous edema, missing ribs, and delayed sternebrae ossification. 
Rats exposed to chloroform at 300 ppm ate so little food (1 g/day) that it 
would be impossible to consider any of the other effects as characteristic 
of chloroform. [83]
Kylin et al [78] found that mice exposed to 100 ppm chloroform for 4 
hours showed moderate fatty infiltration and degeneration at the periphery 
of the liver lobules, one day after exposure. These effects were found 
less frequently 3 days after exposure, indicating a certain amount of 
regeneration. A direct dose-response relationship, evidenced by increasing
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liver alterations and necrosis, was observed at concentrations ranging from 
100 to 800 ppm. Further indication of a dose-response relationship was the 
increase of the serum ornithine carbamoyl transferase with increasing 
concentrations of chloroform.
Animal studies [95] have shown that chloroform is capable of causing 
liver and kidney injury after 130 repeated 7-hour exposures to
concentrations as low as 25 ppm. Injury at that exposure level was minor
and reversible; at higher concentrations (50 and 85 ppm) repeated exposure 
produce more severe injury but no changes in clinical chemical tests for 
such injury. Repeated 4-hour exposures to 25 ppm caused no effect. From
this study, it was suggested that a ceiling of 25 ppm would be more
appropriate, with the TWA concentration not to exceed 10 ppm.
A summary of concentration-responses data is presented in Table X-
11 .
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IV. ENVIRONMENTAL DATA AND BIOLOGIC EVALUATION
Environmental Concentrations
Environmental data derived from the manufacture and use of 
chloroform are very scarce. The only industrial environmental data 
available are from surveys of the pharmaceutical industry where the 
chloroform consumed is less than 10% of the total produced. Although 
fluorocarbon refrigerants and resins account for almost 90% of the 
chloroform used in the United States, [96] there are no studies on workroom 
concentrations of chloroform used in their production.
Challen et al [67] in 1958 studied chloroform concentrations in a 
confectionery manufacturing plant in England, in which chloroform vapor 
were given off during the production of medicinal lozenges. Employees had 
complained about exposure to chloroform and subsequently a system of 
exhaust ventilation was installed. An air sample was taken continuously in 
the breathing zone of the operator during a period of 20 minutes coinciding 
with the duration of the ingredient mixing process. The sample was drawn 
through 2 U tubes containing dried silica gel at the rate of 1 liter/min. 
Additionally, at a point in the operation where a peak concentration was 
expected, a 6-liter grab sample was taken. Air samples of 30-minute 
durations were also taken in the breathing zones of cutting room operators 
performing 3 different operations during 2 periods of production on the 
same day under the current ventilation conditions. For purposes of 
allowing a comparison, the original conditions in the cutting room were 
simulated by closing the doors and windows and shutting off the ventilation 
system. On the day of the simulated conditions, air samples of 30-minute
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durations each were taken during 3 periods of production in the breathing 
zone of operators performing the 3 different operations and in the general 
room air. All samples were analyzed by the alcohol KOH combustion method 
(alkali hydrolysis).
Under the current conditions of ventilation, the continuous sample 
taken during the mixing operation contained 128 ppm, and a peak value of
1,163 ppm of chloroform lasting 1 1/2 minutes was found in the grab sample 
of air adjacent to the emptying of the mixer. The mixing operation 
occurred no more than 4 times daily for a total of about 2 hours. In the 
cutting room, the environmental concentrations were: feeding operation, 71
and 57 ppm; dusting operation, 35 and 31 ppm; and tray removal, 23 and 29
ppm.
Chloroform concentrations in the air found by Challen et al [67]
during the simulation of the original conditions were as follows: feeding
operation, 219, 237, and 161 ppm; dusting operation, 110, 158, and 155 ppm; 
removing trays, 77 and 92 ppm; general atmosphere at the center of the
room, 82 and 92 ppm.
Concentrations of chloroform during the years 1968-72 in a plant
manufacturing film were supplied by the Department of Labor and Industries, 
Commonwealth of Massachusetts. [LD Pagnotto, written communication, 
December 1973] A solvent mixture containing 75% methylene chloride, 22% 
chloroform, and toluene was used in the operation. Samples were collected 
by drawing air at a rate of 0.5 liters/min for 90-120 minutes through a U- 
tube filled with 7 g of silica gel and desorbed by soaking in isopropyl 
alcohol for 2 hours. Aliquots of this solution were hydrolyzed by
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potassium hydroxide (KOH) for 17 hours, and for 65 hours in order to 
estimate both chloroform and methylene chloride.
To differentiate between the amounts of chloride recovered from 
chloroform and methylene chloride, it was necessary to use empirical 
chloride recovery factors determined from control samples analyzed in 
parallel. During the first 17 hours of hydrolysis, averages of about 4% of 
the methylene chloride and about 80% of the chloroform were hydrolyzed. 
During hydrolysis an average of about 20% of the methylene chloride, but 
virtually no additional chloroform was hydrolyzed. It was necessary to run 
methylene and chloroform controls for each determination.
Over the 5 years of surveillance, a total of 79 samples were 
determined by this method. The measured concentrations of chloroform 
ranged from 7-170 ppm, with a mean of 47 ppm. On 2 consecutive days in 
1973, samples were collected on charcoal and analyzed by GC. On these 2 
days concentrations ranged from 30-585 ppm, and in general, appeared to be 
higher than concentrations previously observed by the silica gel-alkaline 
hydrolysis method.
Bomski et al, [55] while investigating the health of workers in a 
pharmaceutical plant in Poland, repeatedly measured chloroform 
concentrations in the air of the production rooms. No information was 
given about the time span covered by the investigation, the number of air 
samples collected, or the duration of individual sampling times. The range 
of concentration reported was between 2 and 205 ppm (0.01-1.0 mg/liter) 
determined by the method of Grabowicz. [68] This method is a modification 
of the Fujiwara colorimetric method which is explained in detail in the 
following section.
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Environmental Sampling and Analytical Method
(a) Collection Methods
Most of the analytical methods are dependent on the effectiveness 
and reproducibility of the sorption of chloroform on or in different col­
lecting media.
Air samples should be collected and transported to a laboratory, 
then desorbed or chemically treated, and finally analyzed quantitatively. 
Silica gel has been used extensively in the past as a collection medium. 
[67,97] Silica gel is a polar adsorbent and shows pronounced selectivity 
in adsorbing polar molecules, particularly water. Hence, when sampling 
large volumes, the atmospheric moisture may compete for the adsorptions 
sites and displace the chloroform being sought. When sampling large 
volumes (more than 3 liters), the silica gel adsorption tube may become 
saturated with water thus impairing the retentive properties of the collec­
tion medium. [98]
Activated charcoal as a collection method has been used in conjunc­
tion with gas chromatography. [99] Activated carbon is nonpolar and will 
consequently adsorb organic vapors in preference to water vapor so that 
sampling of volumes higher than 3 liters can be accomplished without 
noticeable moisture interferences. [98]
Williams and Umstead [100] have developed a collection method in 
which atmospheric samples are concentrated on porous polymer beads. The 
same column utilized for sample collection is subsequently used for GC 
analysis. The advantage of this method is that it integrates collection and
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analysis into one operation. However, it has not yet been developed for 
field use.
Liquids have been used as collection absorbers of chloroform 
contaminated atmospheres. Impingers containing m-xylene [101] were used as 
collectors for gas chromatographic analysis and bubbler bottles containing 
a pyridine solution were also used as the collection method in conjunction 
with colorimetric analysis. [97] The use of liquid impingers and bubblers 
poses problems in field measurements due to difficulties in collecting 
breathing zone samples without spilling of liquid and the added problem of 
transporting liquid samples for laboratory analysis.
Other investigators have collected the contaminated atmospheres 
directly by grab samples using a variety of containers ranging from plastic 
bags to hypodermic syringes. [99] However, the small amounts collected do 
not accurately represent the atmosphere in a plant location during a work 
shift.
(b) Desorption Methods
When solid collection media are used it is necessary to desorb the 
contaminant collected on the medium. Isopropyl alcohol and heat were used 
by the Massachusetts Department of Labor and Industries to desorb 
chloroform from silica gel. Desorption from charcoal was studied by 
Otterson and Guy. [99] They recommended the use of different desorbing 
agents depending upon the comparative gas chromatograph retention times for 
the desorber and the contaminant. Carbon disulfide was determined to be 
the best desorbent for chloroform.
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(c) Analysis
Several methods have been used to determine the concentration of 
chloroform in the air. The analytical methods can be divided in 2 broad 
categories: 1) methods based on chloroform chemical reactions; and 2)
methods based on chloroform physicochemical characteristics.
The 3 chemical methods that have been used extensively are: 1)
dechlorination of collected vapor samples with strong alkalis followed by 
titration of the chloride ion (alkali hydrolysis) [34,67]; 2) colorimetric 
measurement of the reaction products of chloroform and pyridine heated in 
alkali solution (Fujiwara reaction) [102]; and 3) direct reading 
colorimetric indicators. [103]
The dechlorination method (alkali hydrolysis) requires collection of 
the chloroform contaminated atmosphere over a suitable collection medium 
followed by hydrolysis in isopropyl alcohol. Solid KOH is added and the 
mixture is allowed to sit overnight (about 20 hours). After neutralization 
the liberated chloride ion is titrated with silver nitrate. [97] The
percentage of chlorine hydrolyzed is determined by comparison between 
samples and known controls. This method has the disadvantage of a long and 
elaborate procedure in which the amount of chloride ion liberated depends 
on the duration of the process of alkali dechlorination. When a mixture of
chlorinated hydrocarbon vapors is analyzed, there is the additional problem
of specificity; it is necessary then to differentiate the contribution of 
each chlorinated compound to the total amount of chloride ion liberated. 
[LD Pagnotto, personal communication, 1973]
In the colorimetric analytical method based on the Fujiwara
reaction, [102] a stream of air containing chloroform is passed through a
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washer bottle containing pyridine at a rate of 0.5 liter/min. After 
collection in pyridine, methylethyl ketone and NaOH are added to an aliquot 
of the sample. A control and an aliquot of the former solution are heated 
in a boiling water bath, and cooled during a fixed time period. The ab­
sorption is then determined with a suitable spectrophotometer. This method 
requires less time than the dechlorination method, but the problem of 
specificity in the presence of mixtures of other chlorinated hydrocarbons 
remains.
The third chemical method consists of direct reading indicators, 
[103] which are glass tubes packed with solid chemicals that change colors 
when measured and controlled flow of air containing chloroform passes 
through the packed material. There are 2 types of sampling procedures: 1)
direct passing of the test vapor through the tube followed by comparison 
with a calibration chart; 2) drawing the test vapor into a pyrolyzer 
accessory prior to detection. [104] Both methods are nonspecific for 
chloroform since the liberated halogen ion produces the stain to be read 
and any halogen or halogenated compounds will interfere. Regulations on 
detector tubes are found in 42 CFR Chapter I, subchapter G, Part 84, Sub­
part B, paragraph 84.20 (e). These regulations provide that measurement 
with colorimetric indicator tubes should be correct within ± 25% of the
values read. There are commercially available detector tubes which fulfill 
this criterion.
The category of analytical methods, based on the physicochemical 
properties of chloroform, includes: gas chromatography (GC), [105] infrared 
spectrometry (IR), [106] and photodetector analyzers (Davis Halide Meter). 
[107] The gas chromatographic method of analysis provides a specific
63
quantitative analytical method. [105] Gas chromatographic analysis is 
specific for different chlorinated hydrocarbons since every compound has a 
specific retention time in a given chromatograph column. However, there is 
the possibility that several compounds in a mixture may have similar 
retention times. This problem is easily overcome by altering the 
stationary phase of the chromatograph column by changing the column 
temperature or other analytical parameters. Altering conditions will 
usually change the retention times and separate the components.
A mass spectrometer in conjunction with the gas chromatograph could 
be used to identify unknown chemicals passing through the chromatograph 
column. A charcoal capillary tube is employed to trap and transfer the 
observed unknown GC peak to a mass spectrometer for qualitative identifi­
cation as described by Cooper et al. [108]
The use of an infrared spectrophotometer [106] provides the advan­
tages of an instantaneous reading of exposure levels of vapors and, in con­
junction with a recorder, can document concentration levels during a com­
plete operation cycle. The IR spectrophotometer eliminates the necessity 
of collecting and transporting samples to a laboratory for analysis. This 
analytical method has been used for continuous monitoring of industrial op­
erations with chlorinated hydrocarbon exposures. [106] However, complicated 
instrumentation is necessary to draw the samples and record the data 
continuously. There is also the need to assure that the atmosphere of 
relevant working stations is sampled and that such samples correspond to 
the breathing zone of the workers at the working stations. [106] There are 
also possibilities of interferences with other air contaminants which are
64
not easy to detect or resolve without expertise in infrared 
spectrophotometry.
Halide meters (Davis Halide Meters and modifications) are based on 
the detection of the increased brightness of an a-c arc (metal electrode) 
when enveloped by an atmosphere contaminated with halogenated hydrocarbons. 
[107] The instrument is sensitive to all halogens and halogenated compounds 
and consequently is nonspecific for chloroform. The Halide meter seems 
suitable for continuous monitoring if there is only chloroform present as 
the air contaminant.
(d) Conclusions and Recommendations
(1) Compliance Method
On the basis of the review of the analytical methods it is 
recommended that gas chromatography be chosen as the compliance method. 
The method is recommended in conjunction with activated charcoal tubes as a 
collection method and the use of carbon disulfide as a desorbent.
The combined collection-desorption analytical method was first 
evaluated in laboratory trials by Otterson and Guy. [99] Fraust and 
Hermann [109] evaluated the optimal charcoal granule size, sampling rates 
and total volume for charcoal sampling tubes. White et al [110] applied 
the findings of Fraust and Hermann [109] and in addition determined the 
optimal cross section of the charcoal tubes and the optimal number of 
collecting sections. The tubes were further modified for use as personal 
samplers for chlorinated hydrocarbon vapor exposures. [Ill]
The reasons for the choice of gas chromatography - activated carbon 
collection as the compliance method are:
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(A) Charcoal tubes are easy to prepare, ship,
and store.
(B) Estimation of exposure with personal 
samplers is easily achieved.
(C) Desorption with carbon disulfide is 
efficient and reproducible.
(D) Gas chromatography identifies chloroform in 
combination with many other compounds.
(E) At the sample volumes recommended, 
interference by moisture is minimal.
(F) The sampling tubes and personal pumps are
commercially available.
However, a disadvantage of the method is the indirect system of 
measurement requiring collection and desorption prior to analysis.
(2) Monitoring Methods
It is also recommended that direct reading colorimetric 
tubes (gas detection tubes) be used as an inexpensive way to determine 
whether exposure, as defined in Chapter I, exists. The tubes must be used 
with manufacturer’s instructions and for monitoring purposes only.
For situations in which there is a continuous and constant 
chloroform use (fluorocarbon refrigerants and resins production, 
manufacture of chloroform, and some pharmaceutical uses), the establishment 
of a continuous monitoring system of the working location is suggested. 
The work place should be monitored by a multiprobe continuous air sampler 
in different working locations, at the breathing zone of the workers
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involved. An appropriate motion-time study at the different probe 
locations will determine the worker TWA exposure.
The analytical apparatus for continuous monitoring should be a cali­
brated infrared spectrophotometer or, if the only halogenated hydrocarbon 
present is chloroform, a halide meter. If various other halohydrocarbons 
are present a gas chromatograph should be used. The continuous monitoring 
findings should be corroborated with the compliance method described in 
Appendix I.
Biologic Evaluation of the Environment
Lehmann and Hasegawa [34] are the only investigators who have 
studied concentrations of chloroform in exhaled air of persons with known 
exposures. The data are presented in Table X-3. One subject was exposed 
to 4,400 ppm (21.5 mg/liter) for 30 minutes, and the concentrations in the 
exhaled air were followed during the first 30 minutes after the end of 
exposure. The average concentrations in the exhaled air collected during 
the 3 immediately consecutive 10-minute postexposure periods were 1.70, 
0.97, and 0.85 mg/liter, respectively.
The other subject was exposed by Lehmann and Hasegawa [34] for 15 
minutes to chloroform at 7,200 ppm (35.3 mg/liter) and the concentration in 
the exhaled air was followed for 20 minutes after the end of exposure. The 
average concentrations in the exhaled air collected during the 3 
immediately consecutive 5-minute postexposure periods were 2.31, 1.48, and 
1.04 mg/liter, respectively. These data show that exhaled breath concen­
trations of chloroform are dependent upon exposure concentration, exposure 
time, and the time after exposure that the air is sampled. In order to
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evaluate exposure to chloroform, data are needed which take these 3 factors 
into consideration.
Chloroform concentrations in the blood have been measured during and 
following anesthesia. [44,50] These data show that chloroform in the blood 
is eliminated rapidly at first but that some remains for at least 8 hours 
after exposure to anesthetic concentrations. These data are inadequate for 
evaluating industrial exposure.
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V. DEVELOPMENT OF A STANDARD
Basis for Previous Standards
In 1946, the Sub-Committee on Threshold Limits of the ACGIH 
published a list entitled "Maximum Allowable Concentrations of Air 
Contaminants for 1946", with the understanding that the list would be 
revised each year. [112] The list of values was compiled from 3 sources:
(a) The list reported by the Sub-Committee on Threshold Limits
at the 5th Annual Meeting of the ACGIH in 1942.
(b) The then comprehensive list published by Cook in Industrial
Medicine. [113]
(c) Published values of the Z-37 Committee of the American Stan­
dards Institute.
The value proposed for chloroform by the ACGIH [112] was 100 ppm.
In 1959, the Threshold Limit Value (TLV) for chloroform was reduced 
to a time-weighted average of 50 ppm for a normal working day by the ACGIH 
[114] in their annual review of the TLV values.
In 1962, the ACGIH [115] published its Documentation of Threshold 
Limit Values (TLV's) in which it cited the recommendations of Cook [113] 
that exposures to chloroform be kept below 50 ppm, and the study of Challen 
et al. [67] The 1968 TLV, which was unchanged from the 1962 
recommendation, was promulgated $s a regulation by OSHA. This was 
published, apparently in error, as a ceiling value of 50 ppm, in the 
Federal Register, volume 39, page 23541, dated June 27, 1974.
In 1969, the ACGIH changed the time-weighted average limit to a 
ceiling and documented this in 1971. [116] This ceiling limit of 50 ppm
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was considered adequate to prevent any serious short-term effects on the 
liver, but it was recommended that chloroform be used with close medical 
surveillance, particularly with those workers who consume alcohol. The 
recommendation was based in part on the studies of Challen et al, [67] 
Bomski et al, [55] and unpublished data from the Massachusetts Division of 
Occupational Hygiene. A notice of intended change for chloroform from 50 
(ceiling) to 25 ppm (time-weighted average) was made by the ACGIH in 1972 
[117] and 1973. [118]
The AIHA Hygienic Guide Series of 1965 for Chloroform [95] suggested 
that a time-weighted average (TWA) of 10 ppm be used with a ceiling of 25 
ppm. This recommendation was based on unpublished experimental animal 
data.
In 1970, the International Labour Office in Geneva published tables 
of Permissible Levels of Toxic Substances in the Working Environment . for 
many countries. [43] The chloroform standards for 8 different countries 
are listed below; it is not clear from the reference whether these are 














Basis for Recommended Environmental Standard
The major exposure to chloroform has been as an anesthetic 
[33,44,50,58] and most experiments have been related to this use. Cardiac 
arrhythmias have occurred, especially when chloroform anesthesia has been 
prolonged beyond 30 minutes. [56,57] Liver and kidney injuries have also 
been found, sometimes resulting in death several days after anesthetic 
exposure. [30,36,44,46,47,53,94]
It is difficult to evaluate the total exposure to chloroform during 
anesthesia since concentrations frequently were not reported. However, it 
should be noted that the concentrations in anesthesia are extremely high 
and are not constant throughout the exposure period. Whipple and Sperry
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[30] demonstrated in experiments with dogs that chloroform anesthesia for a 
period of 1-2 hours caused central liver necrosis. At autopsy of a woman 
who had died from delayed chloroform poisoning, they found liver changes 
that resembled changes found in dogs. The only other experimental study of 
liver changes after inhalation of chloroform was that by Kylin et al [78] 
in 1963 who exposed 20 mice to 100, 200, 400, and 800 ppm for 4 hours. In 
this study, the mice exposed to 100 ppm did not develop demonstrable liver 
necrosis, however, moderate fatty infiltration of the liver was noted. In 
mice exposed to 200 ppm, some necrotic areas appeared in the liver and 
there was an increase in serum ornithine-carbamoyl transferase. Exposures 
to 400 and 800 ppm resulted in increasing necrosis and serum enzyme 
activity.
Although Schwetz et al [83] did not report detailed studies of liver 
changes in female rats exposed to chloroform 7 hours/day for 10 days, they 
did report that liver weights, both absolute and relative, increased as a 
result of exposure to 100 and 300 ppm but not to 30 ppm. However, embryo 
and fetal anomalies, including delayed skull ossification and the formation 
of wavy ribs, were found in the offspring of the rats exposed to 30 ppm.
The only account of liver abnormalities among industrial workers 
exposed to chloroform is a report by Bomski et al. [55] These investi­
gators found 17 cases of hepatomegaly in a group of 68 workers exposed to
chloroform in concentrations ranging from 2-205 ppm for 1-4 years in a 
pharmaceutical firm. Three of the 17 workers with hepatomegaly were judged 
by the authors to have toxic hepatitis on the basis of elevated serum
enzymes, and elevated serum gamma globulin. This group of workers was also 
considered to be much more susceptible to viral hepatitis than the
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inhabitants of the city in which the plant was located, but the basis for 
this inference is tenuous, since no information was given on possible 
contributions to the problem by poor sanitation, for example the incidence 
of viral hepatitis in other plant workers was not mentioned.
In the study by Challen et al [67] no liver abnormalities were found 
among 17 workers exposed to chloroform. Nine workers were exposed to 
chloroform at TWA concentrations ranging from 23-71 ppm, but for only 4 
hours/day. These workers had been working under these conditions for 10-24 
months. Another group of workers who had previously been exposed to 
chloroform in concentrations estimated to have ranged from 77-237 ppm for 
up to 8 hours/day, also had no abnormal liver findings. However, it had 
been many months since this latter group had been exposed to chloroform.
These studies indicate that liver damage may occur in workers from 
exposure to chloroform in varying concentrations up to 205 ppm. [55] The 
studies with mice showed some liver cell necrosis from 4 hours' exposure to 
200 ppm and fatty infiltration of the liver from 100 ppm for 4 hours. [78] 
The studies with rats showed increased liver weights from 10 consecutive 7- 
hour daily exposures to 100 ppm, but not to 30 ppm exposures. [83] The 
studies by Challen et al [67] indicated no liver injury from 4 hours per 
day exposure of workers to 23-71 ppm chloroform.
While the exposure conditions studied by Challen et al [67] (23-71 
ppm chloroform for 4 hours/day) seem below the threshold for liver injury, 
they are not adequate to protect workers from other undesirable responses 
such as dryness of the mouth and throat at work, and lassitude in the 
evening, which occurred among the workers exposed to 23-35 ppm chloroform 
for 4 hours a day. It seems reasonable to infer from these observations
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that the lassitude reflects central nervous system depression and that dry 
mouth and throat and the digestive tract symptoms reflect a local irritant 
action in those areas.
It can be interpreted from the study of Challen and co-workers [67] 
that a safe level to exposure for workers lies somewhere between 23 and 35 
ppm for 4-hour workdays, or about 10 to about 18 ppm for 8-hour workdays. 
The appropriate limit within this range is not clear, but because of mild 
effects in this group (mouth and throat dryness and evening fatigue) and 
because of the fetal abnormalities found in rats exposed to 30 ppm, [83] it 
is concluded that the environmental limit to be recommended should be the 
lowest in this range, namely 10 ppm, as a time-weighted average.
The absorption of chloroform resulting from exposure to a given 
time-weighted average concentration for 8 hours a day, 5 days a week, would 
be about the same as that absorbed for 10 hours a day, 4 days a week.
Thus, the same time-weighted average limit is applicable whether the 40- 
hour workweek is applied over 5 8-hour days or 4 10-hour days.
It is likely that a central nervous system depressant, such as
chloroform, might at briefly high concentrations affect attention, judgment 
or perception sufficiently so that if an emergency were to occur the worker
might not take appropriate action. This suggests the need for a ceiling
concentration to be observed, as a limitation on excursions above the time- 
weighted average and as a limit applicable to occasional and brief use of 
chloroform. However, after detailed consideration of the data applicable 
to derivation of such a ceiling, no basis from the scientific data appears. 
The ceiling proposed by American Industrial Hygiene Association [95] in its 
Hygienic Guide Series is based on animal data that seem more applicable to
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development of a time-weighted average limit. Thus, a ceiling limit of 50 
ppm based on a 10-minute sampling period is proposed on the basis of good 
practice.
It is recognized that many workers handle small amounts of
chloroform or are working in situations where, regardless of amounts used, 
there is only negligible contact with the substance. Under these 
conditions, it should not be necessary to comply with all provisions of 
this recommended standard, which has been prepared primarily to protect 
worker health under hazardous circumstances. On the other hand, concern 
for worker health requires that protective measures be instituted below the 
enforceable limit to ensure that exposures stay below that limit. For
these reasons, "exposure to chloroform" has been defined as exposure above 
half the environmental limit, thereby delineating those work situations 
which do not require the expenditure of health resources for environmental 
and medical monitoring and associated recordkeeping. Half the
environmental limit has been chosen on the basis of professional judgment 
rather than on quantitative data that delineate nonhazardous areas from
areas in which a hazard may exist. However, it is recommended that 
appropriate work practices and protective measures to prevent skin and eye 
contact and to prevent exposure to pyrolysis products be required, 
regardless of air concentrations of chloroform.
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VI. WORK PRACTICES
The principal method for the manufacture of chloroform is 
chlorination of methane, [1] and suitable controls for safe use of methane 
and chlorine should be used. Engineering controls required for the safe 
handling of chlorine are available. [119]
Further information concerning specific work practices for 
chloroform such as engineering controls, preventive measures, medical 
management, first aid, training, safety, etc, can be found in the 
Manufacturing Chemists' Association Safety Data Sheet SD-89. [120]
(a) Bulk Handling
Of primary concern in bulk loading or unloading operations is the 
possibility that an emergency situation may arise as a result of equipment 
breakdown or failure to follow proper work procedures. All piping and 
valves at the loading or unloading station should be carefully inspected 
prior to connection to the transport vehicle and periodically during the 
operation. Personal protection must be provided during both inspection and 
connection. Eye wash and safety shower installations should be readily 
available in the immediate area. Unloading areas must be posted "Danger: 
loading or unloading chloroform".
(b) Storage and Use
Although chloroform is noncombustible, decomposition to toxic 
compounds including phosgene, tetrachloroethylene, hydrogen chloride, 
chlorine and carbon dioxide may occur in case of a fire. [1]
Protective measures include use of closed systems whenever feasible, 
personal protective equipment, protective clothing, purging of equipment
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prior to and during servicing and maintenance, and well designed and 
properly functioning laboratory hoods and exhaust systems. In general, 
good engineering practices should be used to control continuous low-level 
exposures and to minimize excursions. For example, good ventilation 
practices are recommended in Industrial Ventilation-A Manual of Recommended 
Practice [121] published by the American Conference of Governmental 
Industrial Hygienists. Special handling and disposal procedures are also
required because of the ability of chloroform to undergo chemical reactions 
with other materials. For example, chloroform reacts violently with
acetone in the presence of alkali and also with alkali metals. It reacts 
less violently with caustic. For these reasons, chloroform should not be 
disposed of along with other waste solvents. The ability of some 
chlorinated solvents to react with aluminum producing anhydrous aluminum 
chloride suggests that chloroform should not be stored in aluminum 
containers.
Safety showers and eye wash fountains are necessary in areas where 
accidental exposure is likely to occur.
(c) Maintenance of Equipment
All equipment used for handling chloroform must be emptied and 
purged prior to entry or disassembly. Under conditions where it is 
necessary to enter or otherwise work with chloroform contaminated equipment 
maintenance personnel must use either a self-contained breathing apparatus, 
pressure demand type, with an impervious protective suit; or a combination 
supplied air suit with auxiliary self-contained air supply. Safety 
precautions for emergency rescue require that all maintenance personnel be 
informed of wearing personal protective equipment. [2]
77
(d) Emergencies
Spills must be anticipated. Storage tanks should be diked to 
contain the contents of the tank. Drum storage areas must also be diked to 
contain the volume of chloroform present in the drums so as to prevent 
release to other areas. Areas where major spills are likely to occur 
should be constructed so that they may be closed until properly protected 
personnel can enter, clear and ventilate the area. Normal work should not 
be continued until the concentration of chloroform has been reduced to that 
prescribed by this standard. Sewering of chloroform should be done in
compliance with local, state, and federal waste disposal regulations. 
Consideration should be given to pumping the diked spill to another tank. 
In addition, it is advisable to have facilities for transfer of the
contents of a leaking tank to another suitable tank.
(e) Respiratory Protection
For adequate respiratory protection against the multiplicity of con­
ditions which may be encountered in individual operations, many types of 
respirators have been developed and approved. Each has a particular field 
of application and limitations from the viewpoint of protection, as well as 
advantages and disadvantages from the viewpoint of operational procedures 
and maintenance. Detailed information on the selection and use of
respirators can be obtained from the respiratory protection devices manual 
[122] published by the AIHA and the ACGIH in 1963. The American National 
Standards Practices for Respiratory Protection, ANSI Z88.2-1969, [123] also 
classifies, describes, and gives the limitations of respirators.
Respirators generally fall into the following classification 






(D) Combination self-contained and airline.
(2) Air-Purifying Respirators
(A) Gas and vapor (gas mask and chemical
cartridge).
(B) Particulate (dust, fog, fume, mist, smoke,
and sprays).
(C) Combination gas, vapor, and particulate.
(3) Combination Atmosphere-Supplying and Air-Purifying
Respirators
The factors that affect the overall performance of an air- 
purifying respirator are the reliability of the face seal, the efficiency 
of the filters and/or absorbent canisters and other variables, such as 
leakage from exhalation valves. The performance of filters, canisters, and 
exhalation valves is predictable and controllable when test data are 
available. However, the current state of knowledge of the wearer's face 
size and shape and the respirator size and shape is such that the face seal 
is unpredictable and variable.
During the past several years, NIOSH has funded research and 
development projects to make quantitative respirators-man tests on all 
types of respirators to measure their performance and/or efficiency. The 
results of these tests made on half mask and quarter mask facepieces, 
operated with a negative pressure in the facepiece, show that the facepiece
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leakage is the major limitation of these devices. From the test results, 
it has been demonstrated that the half mask or quarter mask facepiece may 
be Used for protection up to 10X the TWA. The full facepiece, operated 
with a negative pressure, may be used up to 100X the TWA. The majority of 
the wearers can obtain a higher degree of protection. However, for 
purposes of uniform regulations, covering the many face sizes and shapes of 
the US working population, it is necessary to use these guides. These 
maximum use concentration guides do not take into account additional 
leakage from filters or canisters.
When providing respiratory protection against chloroform, the 
concentration immediately dangerous to life must be considered. In this 
document, it is assumed that any concentration of chloroform greater than 
2,500 ppm is immediately dangerous to life.
In selecting and using gas masks and chemical cartridge respirators, 
the service life must be considered. The approval tests (under 30 CFR 11) 
for these 2 devices specify only carbon tetrachloride for the service life 
test. Based on recent tests by Nelson and Harder [124] who tested standard 
respirator cartridges against many types of industrial organic solvents, it 
is now possible to estimate the service life of approved organic vapor 
canisters or cartridges against chloroform. With a test concentration of
1,000 ppm of chloroform, they reported that the standard organic vapor 
cartridge has a service life of 33 min before a breakthrough of 10 ppm of 
chloroform. Under the same test conditions, a service life of 77 min for 
carbon tetrachloride was obtained. Since the approval test for organic 
vapor cartridges and canisters specifies carbon tetrachloride as a test 
atmosphere, it is possible to extrapolate or calculate service life at
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various concentrations of chloroform. For example, the standard industrial 
size gas mask canister is tested against 20,000 ppm of carbon tetrachloride 
and it must have a service life of 12 min before a breakthrough of 5 ppm. 
Extrapolation indicates that the same canister would provide a service life 
of 4 hours against 1,000 ppm of carbon tetrachloride. However, the same 
organic vapor canister is much less efficient for chloroform. If it is 
assumed that carbon tetrachloride absorption is 100% efficient on activated 
charcoal, then chloroform absorption is only 43% efficient. From this, the 
service life against 1,000 ppm of chloroform for an industrial size 
canister is estimated at 2 hours. The chin-type canister with a much 
smaller volume of sorbent has a service life of 4 hours against 100 ppm of 
chloroform. The shortest service life is the chemical cartridge approved 
for use on chemical cartridge respirators. It has a service life of 3 
hours against 100 ppm for chloroform.
NIOSH periodically issues a list of approved or certified 
respiratory protective devices. All devices approved by the Bureau of 
Mines are listed in Information Circular 8559 and supplements. All types 
of devices certified by the Testing and Certification Laboratory of NIOSH 
are listed in a separate publication. These are available from the Testing 
and Certification Laboratory, NIOSH, Morgantown, West Virginia, 26505.
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VIII. APPENDIX I 
SAMPLING AND ANALYTICAL PROCEDURES 
FOR DETERMINATION OF CHLOROFORM
Atmospheric Sampling
(a) General Requirements
(1) The measurement of air concentrations shall be
within the breathing zone of workers and shall meet the following criteria 
in order to evaluate conformance with the standard:
(2) Samples collected shall be representative of
exposure of individual workers.
(3) Sampling data sheets shall include a log of:
(A) The date and time of sample collection
(B) Sampling duration
(C) Total sample volume
(D) A description of the sampling location
(E) Temperature, pressure, and relative humidity
at time of sampling
(F) Other pertinent information
(b) Breathing Zone Sampling
(1) Breathing zone samples shall be collected as near as
practicable to the face of workers without interfering with freedom of
movement and shall characterize the exposure from each job or specific
operation in each production area.
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(2) An approved, calibrated, battery-operated personal 
sampling pump plus an activated charcoal tube shall be used to collect the 
sample.
(3) The activated charcoal tube shall be attached to the 
clothing of the worker; the shirt collar is convenient for this purpose.
(4) Breathing zone samples shall be collected to permit
determination of TWA workday exposures for every job involving exposure to 
chloroform in sufficient numbers to express the variability of the work
situation. The minimum number of TWA's to be determined is listed in
Section 7 of this standard, according to the number of employees involved.
(c) Apparatus
(1) Pump, battery-operated, complete with clip for 
attachment to the worker or a reliable, calibrated hand pump. All pumps 
and flowmeters must be calibrated with a representative charcoal tube in 
the line.
(2) Charcoal tubes: glass tube with both ends flame-
sealed 7 cm long with a 6-mm O.D. and a 4-mm I.D., containing 2 sections of
20/40 mesh activated charcoal separated by a 2-mm portion of urethane foam.
The absorbing section contains 100 mg of charcoal, the backup section 50 
mg. A 3-mm portion of urethane foam is placed between the outlet end of 
the tube and the backup section. A plug of glass wool is placed in front 
of the absorbing section. The pressure drop across the tube when in use 
must be less than 1 inch of mercury at a flowrate of 1 liter/min.
(d) Calibration of Sampling Instruments
(1) Air sampling instruments shall be calibrated with a
representative charcoal tube in line, over a normal range of flowrates (50-
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1000 ml/min) and pressure drops. Calibration curves shall be established 
for each sampling pump and shall be used in adjusting the pump prior to 
field use. Also calibration curves shall be established for each sampling 
pump after making any repairs or modifications to the sampling system.
(2) The volumetric flowrate through the sampling system
shall be spot-checked and the proper adjustments made before and during 
each study to ensure obtaining accurate airflow data.
(e) Collection and Handling of Samples
(1) Immediately before sampling, break both ends of the 
tube to provide openings at least one-half the internal diameter of the 
tube (2mm).
(2) The smaller section of charcoal is used as a backup 
and should be positioned nearest the sampling pump.
(3) The charcoal tube should be placed in a vertical 
position during sampling with the inlet facing down.
(4) Tubing may be used to connect the back of the tube 
to the pump, but air being sampled should not be passed through any hose or 
tubing before entering the charcoal tube.
(5) The flowrates, sampling time involved and/or the 
total volume of air sampled must be measured accurately. The sample can be 
taken at flow rates of 50-1000 ml/min. Total sample volumes of 1-30 liters 
are recommended. It is also recommended that the sampling be less than 4 
hours.
(6) Measure and record the temperature and pressure of 
the atmosphere being sampled.
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(7) The charcoal tubes should be capped with the 
supplied plastic caps immediately after sampling. Under no circumstances 
should rubber caps be used.
(8) One charcoal tube should be handled in the same man­
ner as the sample tube (break, seal, and transport) except that no air is 
sampled through this tube. This tube should be labeled as a blank.
(9) Capped tubes should be packed tightly after sampling 
to minimize tube breakage during transport.
(10) Charcoal tubes should be shipped separately from
bulk samples.
Sample Analysis
(a) Principle of the Method
(1) A known volume of air is drawn through a charcoal 
tube to trap the chloroform vapor.
(2) The charcoal in the tube is transferred to a small
test tube and desorbed with carbon disulfide.
(3) An aliquot of the desorbed sample is injected into a 
gas chromatograph.
(4) The area of the resulting peak is determined and
compared with areas obtained from the injection of standards.
(b) Range and Sensitivity
(1) The lower limit for detection of chloroform at a 16
x 1 attenuation on a gas chromatograph with a 10:1 splitter is 0.10 
mg/sample. This value can be lowered by reducing the attenuation or by 
eliminating the 10:1 splitter.
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(2) The upper limit value for chloroform is 2.0
mg/sample. This is the estimated amount of chloroform which the front 
section will hold before this compound is found on the backup section. If 
a particular atmosphere is suspected of containing a large amount of 
chloroform, it is recommended that a smaller sample volume be taken.
(c) Interferences
(1) When the amount of water in the air is so great that 
condensation actually occurs in the tube, chloroform will not be trapped.
(2) Any compound which has the same retention time as 
chloroform at the operating conditions described in this method could be an 
interference.
(d) Advantages of the Method
(1) This method is advantageous in that it provides one 
basic method for determining many different organic compounds.
(2) The sampling device is small, portable, and involves
no liquids.
(3) Interferences are minimal, and most of those which 
do occur can be eliminated by altering chromatographic conditions.
(4) The analysis of the tubes is accomplished by using a 
quick instrumental method.
(e) Disadvantages of the Method
(1) The amount of sample which can be taken is limited 
by the weight of chloroform which the tube will hold before overloading.
(2) When the sample value obtained for the backup 
section of charcoal exceeds 25% of that found on the front section, the 
possibility of appreciable sample loss exists.
95
(3) Other chlorinated hydrocarbons may displace 
chloroform from the charcoal.
(f) Apparatus
(1) Gas chromatograph equipped with a flame ionization
detector.
(2) Stainless steel column (20 ft x 1/8 in) with 10%
free fatty acid polymer (FFAP) stationary phase on 80/100 mesh, acid washed 
dimethyldichlorosilane (DMCS) treated Chromosorb W (or equivalent) solid 
support.
(3) A recorder and some method for determining peak
area.
(4) Glass stoppered microtubes. The 2.5-ml graduated
microcentrifuge tubes are recommended.
(5) Microsyringe of 10-jul capacity, and convenient sizes 
for making standards.
(6) Pipets. 0.5-ml delivery pipets or 1.0-ml graduated 
pipets in 0.1-ml increments.
(7) Volumetric flasks of 10-ml capacity or convenient 
sizes for making standard solutions.
(g) Reagents
(1) Spectroquality carbon disulfide
(2) CHC13, preferably chromatoquality grade
(3) Bureau of Mines Grade A helium
(4) Prepurified hydrogen
(5) Filtered compressed air
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(h) Procedure
(1) All equipment used for the laboratory analysis 
should be washed in detergent followed by tap and distilled water rinses.
(2) Preparation of samples
Each charcoal tube is scored with a file in front of the 
first section of charcoal and broken open. The glass wool is removed and 
discarded. The charcoal in the first (larger) section is transferred to a 
small stoppered test tube. The separating foam is removed and discarded; 
the second section is transferred to another test tube. These 2 sections 
are analyzed separately.
(3) Desorption of Samples
Prior to analysis, 0.5 ml of carbon disulfide is pipetted 
into each test tube. ALL WORK WITH CARBON DISULFIDE SHOULD BE PERFORMED 
UNDER A HOOD BECAUSE OF ITS HIGH TOXICITY AND ITS FLAMMABILITY. Tests 
indicate that desorption is complete in 30 minutes if the sample is stirred 
occasionally during this period. The use of graduated glass-stoppered, 
microcentrifuge tubes is recommended so that one can observe any apparent 
change in volume during the desorption process depending on the surrounding 
temperature. The initial volume occupied by the charcoal plus the 0.5 ml 
carbon disulfide should be noted and corresponding volume adjustments 
should be made whenever necessary just before analysis.
(4) Gas chromatographic conditions
Operating conditions for a typical gas chromatograph are:
(A) 85 cc/min (70 psig) helium carrier gas flow
(B) 65 cc/min (24 psig) hydrogen gas flow to
detector
97
(C) 500 cc/min (50 psig) airflow to detector
(D) 200 C injector temperature
(E) 200 C manifold temperature (detector)
(F) Oven temperature 80 C isothermal
(5) Injection
The first step in the analysis is the injection of the 
sample into the gas chromatograph. To eliminate difficulties arising from 
blowback or distillation within the syringe needle, the solvent flush 
injection technique is employed. The 10-/ul syringe is first flushed with 
carbon disulfide several times to wet the barrel and plunger. Three ill of 
carbon disulfide are drawn into the syringe to increase the accuracy and 
reproducibility of the injected sample volume. The needle is removed from 
the carbon disulfide solvent, and the plunger is pulled back about 0.2~nl 
to separate the solvent flush from the sample with a pocket of air to be 
used as a marker. The needle is then immersed in the sample, and a 5-jul 
aliquot is withdrawn, taking into consideration the volume of the needle, 
since the sample in the needle will be completely injected. After the 
needle is removed from the sample and prior to injection, the plunger is 
pulled back a short distance to minimize evaporation of the sample from the 
tip of the needle. Duplicate injections of each sample and standard should 
be made. No more than a 3% difference in area is to be expected.
(6) Measurement of Area
The area of the sample peak is measured by an electronic 
integrator or some other suitable form of area measurement, and preliminary 
sample results are read from a standard curve prepared as discussed below.
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(A) Preparation of Standards
It is convenient to prepare standards in terms of mg 
chloroform per 0.5 ml of carbon disulfide because samples are desorbed in 
this amount of carbon disulfide. To minimize error due to the volatility 
of carbon disulfide, 20 times the weight can be injected into 10 ml of
carbon disulfide. For example, to prepare a 0.3 mg/0.5 ml standard, 6.0 mg
is injected into exactly 10 ml of carbon disulfide in a glass stoppered 
flask. The density for chloroform is used to convert 6.0 mg into micro­
liters for easy measurement with a microliter syringe. A series of 
standards are prepared, varying in concentration over the range of interest 
and analyzed under the same gas chromatographic conditions and during the 
same time period as the unknown samples. Curves are established by
plotting concentration versus average peak area.
(B) Determination of Desorption Efficiency
It is necessary to determine the percentage of 
chloroform on the charcoal that is removed in the desorption process. This 
desorption efficiency is determined once for a given compound provided the 
same batch of charcoal is always used.
Activated charcoal, equivalent to the amount in the first section of 
the sampling tube (100 mg), is measured into a 2-inch long tube, with an 
inside diameter of 4 mm, flame-sealed at one end. This charcoal must be 
from the same batch as that used in obtaining the samples and can be 
obtained from unused charcoal tubes. The open end is capped with parafilm.
(7) Calibration and Standards
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A known amount of the compound is injected directly into the activated 
charcoal with a microliter syringe, and the tube is capped with more 
parafilm.
At least 5 tubes are prepared in this manner and allowed to stand at 
least overnight to assure complete adsorption of chloroform onto the 
charcoal. These 5 tubes will be referred to as the "desorption samples". 
A parallel blank tube should be treated in the same manner except that no 
chloroform is added to it. The desorption sample and blank tubes are 
desorbed and analyzed in exactly the same manner as previously described.
Two or 3 desorption standards are prepared for analysis by injecting 
the same volume of compound into 0.5 ml of carbon disulfide with the same 
syringe used in the preparation of the desorption sample. These are 
analyzed with the desorption samples.
The desorption efficiency equals the difference between the average 
peak area of the desorption samples and the peak area of the blank divided 
by the average peak area of the desorption standards, or
desorption efficiency = Desorption sample area - Blank area
Desorption standard area
Sample Calculations
(a) Read the weight of chloroform corresponding to the peak area 
for chloroform from the standard curve. No volume corrections are needed 
because the standard curve is based on mg CHC13/0.5 ml carbon disulfide, 
and the volume of sample injected is identical to the volume of the 
standards injected.
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(b) Separately determine the weights of chloroform on the front
and backup sections of the charcoal tube.
(c) Corrections must be made to the chloroform weights 
determined on both the front and backup sections for the weights of the 
respective sections of the blank charcoal tube.
(1) Subtract the weight of chloroform found on the front
section of the blank charcoal tube from the weight of chloroform found on 
the front section of the sample charcoal tube to give a corrected front 
section weight.
(2) Subtract the weight of chloroform found on the
backup section of the blank charcoal tube from the weight of chloroform 
found on the backup section of the sample charcoal tube to give a corrected 
backup section weight.
(3) Add the corrected amounts of chloroform present on
the front and backup sections of the sample tube to determine the total 
measured chloroform in the sample.
(4) Divide this total weight by the determined
desorption efficiency to obtain M, the total mg per sample.
(d) Convert the liters of air sampled (V) to volume (V') at 





V1 = volume of air in liters at 25 C and 760 mm Hg 
V = measured volume of air in liters sampled 
P = barometric pressure in mm Hg at time of 
sampling measured 
T = temperature of air in degree centigrade at time 
of sampling measured
(e) The concentration of chloroform in the sampled air can be 
expressed in various ways using M, the weight of chloroform obtained in 
(c) (4)  and V', the standardized sample volume, obtained in (d), as follow:
(1) jug/liter = 1000 M/V’
(2) mg/cu m = 1000 M/V*
(3) ppm = 205 M/V'
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IX. APPENDIX II 
MATERIAL SAFETY DATA SHEET
The following items of information which are applicable to 
chloroform shall be provided in the appropriate section of the Material 
Safety Data Sheet or approved form. If a specific item of information is 
inapplicable, the initials "na" (not applicable) should be inserted.
(a) Section I. Source and Nomenclature.
(1) The name, address, and telephone number of the
manufacturer or supplier of the product.
(2) The trade name and synonyms for a mixture of
chemicals, a basic structural material, or for a process material; and the 
trade name and synonyms, chemical name and synonyms, chemical family, and 
formula for a single chemical.
(b) Section II. Hazardous Ingredients.
(1) Chemical or widely recognized common name of all 
hazardous ingredients.
(2) The approximate percentage by weight or volume
(indicate basis) which each hazardous ingredient or the mixture bears to
the whole mixture. This may be indicated as a range or maximum amount, ie, 
10-20% by volume; 10% maximum by weight.
(3) Basis for toxicity for each hazardous material such 
as an established standard in appropriate units.
(c) Section III. Physical Data.
Physical properties of the total product including boiling point and 
melting point in degrees Fahrenheit; vapor pressure in millimeters of
103
mercury; vapor density of gas or vapor (air=l); solubility in water, in 
parts per hundred parts of water by weight; specific gravity (water=l); 
percentage volatile, indicate if by weight or volume, at 70 degrees 
Fahrenheit; evaporation rate for liquids (indicate whether butyl acetate or 
ether=l); and appearance and odor.
(d) Section IV. Fire and Explosion Hazard Data.
Fire and explosion hazard data about a single chemical or a mixture 
of chemicals, including flash point, in degrees Fahrenheit; flammable 
limits in percentage by volume in air; suitable extinguishing media or 
agents; special fire fighting procedures; and unusual fire and explosion 
hazard information.
(e) Section V. Health Hazard Data.
Toxic level for total compound or mixture, effects of exposure, and 
emergency and first-aid procedures.
(f) Section VI. Reactivity Data.
Chemical stability, incompatibility, hazardous decomposition 
products, and hazardous polymerization.
(g) Section VII. Spill or Leak Procedures.
Detailed procedures to be followed with emphasis on precautions to 
be taken in cleaning up and safe disposal of materials leaked or spilled. 
This includes proper labeling and disposal of containers holding residues, 
contaminated absorbents, etc.
(h) Section VIII. Special Protection Information.
Requirements for personal protective equipment, such as respirators,
eye protection, clothing, and ventilation, such as local exhaust (at site 
of product use or application), general, or other special types.
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Any other general precautionary information.
(i) Section IX. Special Precautions.
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U.S. DEPARTMENT OF LABOR 
Occupational Safety and Health Administration
MATERIAL S A F E T Y  DATA SHEET
Required under USDL Safety and Health Regulations for Ship Repairing, 
Shipbuilding, and Shipbreaking (29 CFR 1915, 1916, 1917)
SECTION I
M A N U F A C T U R E R ’S N A M E EM E R G EN C Y  TE LE P H O N E  NO.
ADDRESS (Number, Street, City, State, and ZIP Code)
C H E M IC A L  N A M E  A N D  S YN O N YM S T R A D E  N A M E  A N D  S YN O N YM S
C H E M IC A L  F A M IL Y F O R M U LA
Form  Approved 
OMB No. 44-R 1387
SECTION II - HAZARDOUS INGREDIENTS
PAINTS, PRESERVATIVES, & SOLVENTS % TLV
(Units) ALLO YS AND METALLIC COATINGS %
TLV
(Units)
PIGMENTS BASE M E T A L
C A T A LY S T A L L O Y S
V E H IC L E M E T A L L IC  C O A TIN G S
SO LVENTS F IL L E R  M E T A LPLUS C O A TIN G  OR CORE F L U X
A D D IT IV E S O THER S
OTHERS
HAZARDOUS M IXTURES OF OTHER LIQUIDS, SOLIDS, OR GASES %
TLV
(Units)
SECTION III - PHYSICAL DATA
B O IL IN G  PO INT (°F .) SPECIFIC G R A V IT Y  (H 2 0 = 1 )
V AP O R  PRESSURE (m m Hg.) PERCENT, V O L A T IL E  BY V O L U M E  (%)
V AP O R  D E N S IT Y  (A IR = 1 ) E V A P O R A T IO N  R A TE  
(   * 1 )
S O L U B IL IT Y  IN W ATER
APP E A R A N C E  A N D  ODOR
SECTION IV - FIRE AND EXPLOSION HAZARD DATA
FLA S H  PO INT (M ethod used) F L A M M A B L E  L IM IT S Lei Uel
E X T IN G U IS H IN G  M E D IA
S PE C IA L F IR E  F IG H T IN G  PROCEDURES
U N U S U A L  F I R E  A N D  E X P L O S I O N  H A Z A R D S
PAGE (1) (Continued on reverse side) Form OSHA-20
Rev. M ay 72
SECTION V - HEALTH HAZARD DATA
T H R E S H O LD  L IM IT  V A L U E
EFFECTS O F O VE R E X P O SU R E
E M E R G EN C Y  A N D  F IR S T  A ID  PROCEDURES
SECTION VI - REACTIVITY DATA
S T A B IL IT Y U N S T A B LE C O N D IT IO N S  TO A V O ID
S TA B LE
INCOMPATIBILITY [ Ik U v O a li to  avo id)
H A Z A R D O U S  DECO M PO SITIO N  PRODUCTS
H A Z A R D O U S
P O L Y M E R IZ A T IO N
M A Y  OCCUR
C O N D IT IO N S  TO  A V O ID
W IL L  N O T OCCUR
SECTION V II - SPILL OR LEAK PROCEDURES
STEPS TO  BE T A K E N  IN CASE M A T E R IA L  IS R E LE AS E D  OR S P ILLE D
W ASTE D ISPO SAL M ETH O D
SECTION V III - SPECIAL PROTECTION INFORMATION
R E SP IR A TO R Y  PR O TEC TIO N  (Specify  type)
V E N T IL A T IO N LO C A L  E X H A U S T S PEC IAL
M E C H A N IC A L  (General) O THE R
P R O TE C TIV E  G LO VE S EYE PR O TEC TIO N
O TH E R  P R O TE C TIV E  E Q U IP M E N T
SECTION IX - SPECIAL PRECAUTIONS
P R E C A U TIO N S  TO  BE T A K E N  IN  H A N D L IN G  A N D  STO R IN G
O TH E R  P R EC A U TIO N S
PAGE (2)




PHYSICAL PROPERTIES OF CHLOROFORM






















61.3 C, 142.3 F (760 mm Hg) 
-63.2 C, -81.7 F 
200 mm Hg (25 C)
1.48069 (25 C), (water =
1.000 at 4 C)
1.0 g/100 ml water at 15 C; 
soluble in ethanol,
ethyl ether, benzene, 
acetone, and carbon disulfide 
None 
None
4.00 g/liter (25 C; 760 mm Hg) 
1 mg/liter = 205 ppm
1 mg/cu m = 0.205 ppm 
1 ppm = 4.89 mg/cu m
Adapted from references 1,2,3,4
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TABLE X-2
PERCENTAGE ABSORPTION OF CHLOROFORM 
AFTER INHALATION BY TWO SUBJECTS
Subject A A A B B B
Inhalation Concentration
ppm 4,448 4,920 5,125 4,264 4,715 4,920
mg/liter 21.7 • 24 25 20.8 23 24
Percent Absorbed
Exposure Period (min)
io 74.5 73.2 75 68.4 49.4 66.4
5-10 72.4 73.2 75 61.6 63.0 64.2
10-15 68.6 69.0 77 51.2 61.6 64.6
15-20 67.6 60.9 76 50.2 53.0 54.4
Adapted from Lehmann and Hasegawa [34]
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TABLE X-3
ABSORPTION OF CHLOROFORM BY SUBJECT C IN CONSECUTIVE 
5-MINUTE PERIODS OF INHALATION OF DIFFERENT CONCENTRATIONS 
OF CHLOROFORM AND EXCRETION OF CHLOROFORM AFTER EXPOSURE
Exposure Inhalation Exposure Percent Postexposure CHC13
Concentration Period Absorbed Period Excretion
ppm mg/liter min min mg/liter
























Adapted from Lehmann and Hasegawa [34]
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TABLE X-4
CASES OF HABITUAL CHLOROFORM USE
Case and Daily Duration Psychiatric and
Reference CHC13 Use of Habit Neurologic Symptoms
1 1 oz daily for 12 years
[36] 7 years, 1 oz
daily for next 
5 years
Restless, distressed, easily 
excitable, depressed, hallu­
cinations, convulsions, 
dysarthria, ataxia, tremor of 
tongue and fingers. Diagnosed 
as having chloroform poisoning 
with cerebellar involvement. 
Autopsy showed moderate 
degenerative changes in 
cerebellum, slightly thickened 






































20-30 g pure 







100 g 15 years
Mental and physical wreck; 
fidgety, nervous, wakeful
After spree - nausea, vomiting, 
and death wish; 2 suicide 
attempts
Mental and physical wreck




delirium, left hemiplegia 
after 9 years, right hemi­
plegia 5 years later
Nervous, unstable, tem­
peramental, overreactive, 
rheumatic pain, slight 
tremor of hands
Psychologically upset 












SGOT, iu 30 681 8,080 5,300 297 34
SGPT, iu 15 9,220 10,250 3,330
LDH, iu 204 636 9,280 5,680 630 176
Alkaline phos­
phatase, iu 6.1 5.2 6.4 5.0
Bilirubin (total),
mg% 0.2 2.3 2.4 2.7 1.3 1.0
Prothrombin
time, sec
a) patient 14.3 19.2 18.4 14.3 12.3
b) control 12.6 11.9 • • • 12.7 11.8 12.2
iu = international units 
... = not reported
Adapted from Storms [41]
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TABLE X-6
SIX CASES OF DELAYED CHLOROFORM POISONING
Patient Dose Effects Laboratory Test­
ane! Autopsy Findings
1 3 administrations Restless, coma and Blood urea: 198 mg/100 cc
(37 yrs 1. 3 capsules, convulsions on 2nd on 3rd day, 303 mg/100 cc
old) each 20 minims day post partum, on 5th day
[45] 2. "very little" vomiting, jaundice, Blood NPN: 187 mg
from drop bottle increased pulse Amino acid nitrogen:
3. 3 capsules, and temperature. 8.2 mg %
each 20 minims Died on 8th day Urine: acid, albumin,
and anesthesia post partum. red blood cells, pus,
on open mask high urobilin 
Liver: soft, yellow 
advanced necrosis, and 
fatty degeneration 
Kidneys: swollen, fatty 
deposits, necrosis 
Heart: fatty degeneration
2 2 inhalations of Drowsy, swelling Blood urea: 105 mg/100 cc
(30 yrs unspecified of hands, jaundice, on 2nd day, 360 mg/100 cc
old) amount separated coma, increased on 5th day
[45] by 2 hours, and temperature and Plasma bicarbonate:
anesthesia on pulse, extreme 0.003 molar
open mask hyperpnea, no 
vomiting.
Died 5th. day post 
partum
Urine: uric acid, 
albumin, pus, 2.35% 
urea on 3rd day 
Liver: yellow, mottled, 
soft, diffuse centri- 
lobular necrosis, fat 
mostly in periphery
3 Full anesthesia
(25 yrs on open mask 
old) "long time" then
[45] repeated 4 hours
later
Drowsy, jaundice, coma Blood: .093 % sugar
on 4th day, muscular 
twitchings, increased
60 mg/100 cc urea 
Urine: deep orange,
temperature, vomiting, ph 6.0, .4 % albumin, 
Died on 6th day post diacetic acid
partum Liver: soft, flabby,
recent shrinkage, yellow, 
widespread necrosis 
Kidneys: congestion




SIX CASES OF DELAYED CHLOROFORM POISONING













Urine: showed albumin, 
bilirubin, urobilin 












over liver, hiccup, 
restless, no vomiting. 
Recovered
Urine: showed albumin, 
bilirubin, urobilin; 
















CLINICAL DATA OF DELAYED CHLOROFORM 









Alkaline phosphatase (1) 21.4-22.3 21.1 •  • «
Carbon dioxide, blood vol % 34 54 45
Blood urea, mg % 108 50 24
Blood chloride, mg % •  • • 570 • •  «
Serum thymol turbidity 0-3.2 2.2 +
(1) King-Armstrong units
Adapted from Lunt [49]
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TABLE X-8
CHLOROFORM IN EXHALED AIR (VOL %) COLLECTED 
DURING THIRD STAGE ANESTHESIA AT INDICATED TIMES 







1 41F Exploration and lysis of adhesions 1 10 1.78
2 73M Biopsy tumor of face 1 10 0.83
3 57M Excision abdominal skin tumor 1 11 0.46
4 56M Resection mandible 1 20 0.64
5 68M Gastric resection 1 84 0.26
5 68M Gastric resection 1 124 0.49
6 42M Laminectomy 1-2 40 0.31
7 58F Radical mastectomy 2 35 0.14
8 38F Partial gastric resection 2 26 0.62
9 44M Gastric resection 2 40 0.24
10 53F Gastric resection; drain gall bladder 2 50 0.34
11 59F Resection cervical nodes 2-3 40 1.47
2 73F Biopsy tumor of face 2-3 40 1.47
1 41F Exploration and lysis of adhesions 3 43 1.57
9 44M Gastric resection 3 123 0.43
Adapted from Morris [50]
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TABLE X-9
THE EFFECT OF CHLOROFORM ON THE URINARY PROTEIN AND URINARY GLUCOSE 














(1) Significant urinary protein = 100 mg % or more
(2) Significant urinary glucose = 250 mg % or more
Adapted from Plaa and Larson [79]
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TABLE X-10
PENTOBARBITAL SLEEPING TIMES OF MICE 24-HOURS 













(1) Sleeping time longer than 6 minutes
Adapted from Plaa and Larson [79]
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TABLE X-ll
CHLOROFORM INHALATION EXPOSURES AND EFFECTS
Author
Exposure

























and Schmidt- 205 ppm 
Kehl [35]
Intermittent Lassitude, dryness of 
4 hrs/day the mouth, irritability
7 hr/day, Delayed fetal skull 
10 days ossification and wavy
rib formation
Intermittent Flatulence, lassitude,














In fetuses - increased 
occurrences of acaudia, 
missing ribs, delayed 
sternebrae ossification, 
subcutaneous edema, 
imperforate anus; in 
adults - increased liver 
weights
Moderate fatty infil­
tration of liver 
some liver necrosis
Headache, nausea, 
burping, loss of appe­
tite, increased inci­
dence of viral hepati­
tis , toxic hepatitis with 
elevated serum gamma 
globulins, splenomegaly, 
hepatomagoly
Perception of light, 
transient odor
Decreased food con^ 
sumption
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TABLE X-ll (Continued) 
CHLOROFORM INHALATION EXPOSURES AND EFFECTS
Exposure
Author Variables Exposure Time Effects
Kyi in 
[78]
400 ppm and 
800 ppm
4 hrs
Lehmann Humans; 922 ppm
and Schmidt- 1,107 ppm 
Kehl [35]
Lehmann Cats; 7,175 ppm
and Schmidt- 
Kehl [35]
Lehmann Humans; 7,236 ppm
and Hasegawa
[34]
























60-285 min Narcosis, respiratory 
fluctuation, decrease 





Humans ; 20,000 ppm
Whipple Dogs; 1-2 oz
and Sperry (total amount 
[30] inhaled)




1-2 hrs Anesthesia, central
hyaline necrosis, acute 
yellow atrophy, fatty 
degeneration of the 
kidneys
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